Fatty Acid and Amino Acid Derivatives in Organocatalyzed Michael Additions

Abstract

Amino acid derivatives, such as β-keto esters and pyrrolones, were used as nucleophiles in organocatalyzed Michael additions to nitroalkene acceptors, while fatty acid derivatives acted as both nucleophiles (β-keto esters) and electrophiles (nitroalkene acceptors). Bifunctional noncovalent organocatalysts were employed as asymmetric organocatalysts. Twenty compounds—including fatty acid and amino acid derivatives, as well as fatty acid–amino acid conjugates—were prepared with enantioselectivities of up to 98% ee. All novel products were fully characterized. This research demonstrates the ease of assembling readily available fatty acid and amino acid building blocks under ambient conditions.

1. Introduction

The enantioselective construction of carbon–carbon and carbon–heteroatom bonds in modern organic synthesis is crucial, as enantiomerically pure compounds play a key role in natural products and pharmaceuticals. Asymmetric organocatalysis, the third pillar of enantioselective catalysis, is a powerful tool that enables the formation of complex products from simple building blocks in an asymmetric manner, without the use of potentially toxic metals and under mild, often non-inert reaction conditions [1,2]. Among numerous organocatalyzed transformations, the asymmetric 1,4-addition to electron-deficient alkenes stands out as a key reaction, serving as a platform for organocatalyst development, the formation of advanced, functionalized, enantiomerically pure building blocks, and target-oriented asymmetric synthesis [3,4,5,6,7,8]. Even after nearly 20 years of intensive research on asymmetric organocatalyzed 1,4-additions, the reaction remains relevant and is applied to various new nucleophile–electrophile starting building blocks [9,10,11,12,13,14,15,16,17,18,19,20].

While various amino acid derivatives, such as β-keto esters [21,22], pyrrolones [22,23,24], azlactones [25,26,27], glycine Schiff bases [28,29,30,31], α,β-unsaturated amino acids [32], α-aryl-α-isocyano acetates [33], α-amino acid-derived thiazolones [34], 1H-imidazol-4(5H)-ones [35], α-imino esters [36], and others, have been used as building blocks in asymmetric organocatalyzed transformations, only a few fatty acid building blocks have been reported in asymmetric organocatalysis. Among the few reports, the enantioselective organocatalytic synthesis of 3-hydroxy fatty acids and fatty γ-lactones is notable [37,38]. Bifunctional phosphorus-based organocatalysts have been used for the atom-economical reaction of CO₂ with epoxidized oleochemicals [39], while amines and alkanolamines as organocatalysts have been used in the amidation of fatty acid methyl esters with 3-(dimethylamino)-1-propylamine [40]. Because fatty acid derivatives exhibit various biological activities, including antitumor [41] and antiproliferative activity [42], inhibition of glioma cell growth [43], activity as inhibitors against Gram-positive Staphylococcus aureus [44], and serving as biomarkers of oxidative stress [45], the demand for simple and efficient enantioselective syntheses—including organocatalytic methods—of fatty acid derivatives continues to grow. On the other hand, nitro fatty acids are an emerging class of bioactive fatty acids [46,47,48,49,50,51,52,53].

We report the synthesis of readily available β-keto ester derivatives of fatty acids and amino acids [22], as well as amino acid-derived pyrrolones used as nucleophiles in the (asymmetric) organocatalyzed Michael addition to fatty acid-derived nitroalkene and trans-β-nitrostyrene [22]. These reactions yield a small library of fatty acid and amino acid derivatives, doubly fatty acid derivatives, and amino acid–fatty acid conjugates. The results highlight the ease of forming these potentially interesting product classes, as well as the drawbacks and challenges encountered.

2. Results and Discussion

Synthesis. β-Keto ester nucleophiles were prepared by Masamune–Claisen homologation of carboxylic acids (Scheme 1) [22]. Activation of Boc-protected glycine 1a, Boc-protected β-alanine 1b, glycolic acid derivative 1c, and palmitic acid (1d), stearic acid (1e), and linoleic acid (1f) with 1,1′-carbonyldiimidazole (CDI) in anhydrous THF, followed by addition of alkyl (methyl, tert-butyl) potassium malonate in the presence of magnesium chloride, afforded the corresponding β-keto esters 2a–g in 45–91% yield. Except for compound 2f, the other β-keto esters are known in the literature and are individually referenced in the Experimental section. β-Keto esters 2h and 2i were prepared in three and five steps, respectively, from H-Orn(Boc)-OMe·HCl (3). Amidation of 3 with stearic acid (1e) gave amido ester 4, which was hydrolyzed under basic conditions to acid 5 and then homologated to β-keto ester 2h in 44% yield over three steps. For the preparation of 2i, compound 4 was Boc-deprotected using TFA to give ammonium salt 6, followed by amidation with stearic acid (1e) to yield diamido ester 7. Hydrolysis of 7 furnished acid 8, which was transformed into β-keto ester 2i in 20% yield over five steps (Scheme 1). Compounds 6–8 and 2i have low solubility in most solvents, including chloroform and dimethyl sulfoxide. Solubility in chloroform increases significantly with the addition of small amounts of trifluoroacetic acid (700 μL CHCl₃ and 20 μL TFA to dissolve 10–20 mg of the above-mentioned compounds).

Scheme 1. Synthesis of β-keto ester building blocks 2a–i.

Similarly, the pyrrolone nucleophiles 11a–c were prepared from appropriately protected phenylalanine 9a, ornithine 9b, and glutamic acid 9c in a two-step procedure (Scheme 2) [22,23]. Initial homologation to the corresponding β-keto esters 10a–c was followed by treatment with N,N-dimethylformamide dimethyl acetal (DMFDMA) at elevated temperature, yielding the corresponding pyrrolones 11a–c in 57–62% yield after two steps. All attempts to prepare the corresponding pyrrolone 11d from amido β-keto ester 2h resulted in complex product mixtures (Scheme 2). In addition to commercially available trans-β-nitrostyrene (12), fatty acid-derived nitroalkene electrophile 16 was prepared in four steps from palmitic acid (1d) following procedures described in the literature [54,55,56]. Reduction of palmitic acid (1d) with LiAlH₄ gave alcohol 13, which was oxidized with pyridinium chlorochromate (PCC) to aldehyde 14. The Henry reaction with nitromethane in the presence of tBuOK afforded β-nitro alcohol 15, which was dehydrated after treatment with trifluoroacetic anhydride (TFAA) and Et₃N at −10 °C to nitroalkene 16 in 38% yield over four steps (Scheme 2).

Scheme 2. Synthesis of the starting building blocks: pyrrolones 11a–c and the fatty acid-derived nitroalkene 16.

Next, the organocatalyzed 1,4-addition of Boc-β-alanine-derived β-keto ester 2b to trans-β-nitrostyrene (12), yielding adduct 17b, was used as a model reaction for catalyst optimization (Scheme 3) [21]. Noncovalent bifunctional organocatalysts I–IX (see ESI, Scheme S1) were tested, and achiral organocatalyst X was used to prepare the racemic product rac-17b. The best results for enantioselectivity, conversion, and reaction profile were obtained with the (+)-cinchonine-derived squaramide catalyst VIII (100% conversion, 85% yield, 95% ee for both diastereomers, (1R)-enantioselectivity), followed by the camphor-derived squaramide catalyst I, which showed the best complementary enantioselectivity (100% conversion, 92% and 93% ee for both diastereomers, (1S)-enantioselectivity). Screening of solvents (toluene, THF, EtOAc, MeCN) revealed broad compatibility of the model reaction catalyzed by VIII (ee between 94% and 96%), except for MeOH (81% and 83% ee) (Scheme 3; for details, see ESI, Scheme S2).

Scheme 3. Organocatalyst and solvent optimization for the addition of Boc-β-alanine-derived β-keto ester 2b to trans-β-nitrostyrene (12). 2b (0.3 mmol), 12 (0.2 mmol), cat. I and VIII (10 mol%), anhydrous CH₂Cl₂ (1.0 mL), 25 °C, Ar, 24 h. Catalyst X was used to prepare rac-17b. ^(a) Two values for the ee, i.e., 95/95, refer to the enantiomeric excess of the C(1) chiral center in the two inseparable diastereomers; the diastereomer ratio of the crude mixtures could not be reliably determined from the corresponding proton spectra.

With optimal reaction conditions established (organocatalyst VIII, dichloromethane, 25 °C), the scope of the organocatalyzed 1,4-additions of β-keto esters 2 to trans-β-nitrostyrene (12) and fatty acid-derived nitroalkene 16 was explored. The achiral bifunctional noncovalent organocatalyst X was used efficiently to prepare all racemic adducts rac-17a–l in 37–88% yield. All doubly fatty acid-derived products rac-17g,i,k, as well as products rac-17c and rac-17e, could not be separated by chiral HPLC. Only the racemic products rac-17a,b,d,f,h,j,l for which all four stereoisomers (two pairs of racemic diastereomers) were separated on a chiral HPLC column, were resynthesized using chiral noncovalent bifunctional organocatalyst VIII (Scheme 4); the corresponding chiral nonracemic products 17a,b,d,f,h,j,l were obtained in 47–89% yield, with high enantioselectivity (91–98% ee) and diastereoselectivity ranging from 50:50 to 64:36. The absolute configuration at the C-2 chiral center is unstable because of rapid keto–enol tautomerization, resulting in low observed diastereoselectivity of the products. Lastly, chiral nonracemic β-keto esters 2h and 2i were used for addition to trans-β-nitrostyrene (12) and fatty acid-derived nitroalkene 16. With the achiral organocatalyst X, addition of 2h to trans-β-nitrostyrene (12) and 16 gave the desired products 17m (71% yield) and 17n (77% yield), respectively, each as an inseparable mixture of four diastereomers in 27:21:24:28 and 26:28:25:21 ratios, respectively. Similarly, addition of 2i to 12 and 16 gave the desired products 17o (29% yield) and 17p (25% yield), respectively, each as an inseparable mixture of four diastereomers in 24:22:30:24 and 25:25:27:23 ratios, respectively. Application of chiral quinuclidine catalyst VIII for the synthesis of products 17n and 17p improved the diastereomer ratio, yielding compound 17n in 88% yield with a 45:11:8:36 diastereomer ratio and compound 17p in 23% yield with a 39:11:12:38 diastereomer ratio (Scheme 4). No attempts have been made to determine the diastereomeric or enantiomeric ratios of compounds 17m–n by HPLC. The stereochemical integrity (enantiomer ratio) of the starting β-keto esters 2h and 2i was not verified; nevertheless, this transformation highlights the challenges encountered—diastereoselectivity and separation of stereomers—in this simple, inherently diastereoselective reaction.

Scheme 4. Scope for the addition of β-keto ester 2 to trans-β-nitrostyrene (12) and fatty acid-derived nitroalkene 16; if not stated otherwise, organocatalyst VIII was used, yielding (1R)-enantioselectivity. Catalyst X was used to prepare the racemic products rac-17a–l. ^(a) 2 (0.3 mmol), 12 or 16 (0.2 mmol), cat. X (20 mol%), I (10 mol%), and VIII (10 mol%), anhydrous CH₂Cl₂ (1.0 mL), 25 °C, Ar, 24–48 h. ^(b) 2 (0.2 mmol), 12 or 16 (0.3 mmol), cat. X (20 mol%), I (10 mol%), and VIII (10 mmol%), anhydrous CH₂Cl₂ (1.0 mL), 25 °C, Ar, 24–48 h. ^(c) In DMSO-d₆. ^(d) In CDCl₃.

Next, phenylalanine-11a, ornithine-11b, and glutamic acid-derived pyrrolones 11c were tested as nucleophiles in the organocatalyzed addition to fatty acid nitroalkene 16 (Scheme 5). Reactions with racemic catalyst X proceeded smoothly, yielding the corresponding products rac-18a–c in 65–77% yields with high diastereoselectivity, ranging from 90:10 to 97:3. Application of the camphor-derived organocatalyst I in anhydrous toluene at room temperature, which were the optimal catalyst and conditions in our previous organocatalyzed additions of pyrrolone nucleophiles to nitroalkene acceptors [23], gave the corresponding chiral products 18a–c in 18–69% yield. For the phenylalanine-derived product 18a (69% yield), the diastereoselectivity remained unchanged at 97:3, with an enantioselectivity of 82% ee for the major diastereomer. For the ornithine-derived adduct 18b and the glutamic acid-derived adduct 18c, the diastereoselectivity with organocatalyst I not only decreased significantly but also reversed, changing from 90:10 to 26:74 for 18b and from 97:3 to 31:69 for 18c. For both diastereomers of product 11b, enantioselectivity could only be tentatively determined due to partial overlap (57% ee for the major diastereomer and 11% ee for the minor diastereomer). Similarly, for product 18c, enantioselectivity was 68% ee for the major diastereomer and 38% ee for the minor diastereomer. Finally, tetronic acid (19) was used as a nucleophile in the addition to nitroalkene 16, yielding the expected product 20 in 44% yield. All attempts to separate the stereoisomers of product 20 were unsuccessful (Scheme 5).

Scheme 5. Scope for the addition of pyrrolones 11 and tetronic acid (19) to fatty acid-derived nitroalkene 16. ^(a) 11 or 19 (0.3 mmol), 16 (0.2 mmol), cat. X (20 mol%) or I (10 mol%), anhydrous PhMe or CH₂Cl₂ (1.0 mL), 25 °C, Ar, 48–72 h. ^(b) In CDCl₃.

Structure determination. The structures of novel compounds 2f, 2h, 2i, 4–8, 16–18, and 20 were confirmed by spectroscopic methods (¹H and ¹³C NMR, IR, and high-resolution mass spectrometry), while compound 15 was used as a crude product for further transformations; its structure was confirmed by ¹H NMR. The diastereomers of compounds 17/rac-17 and 18/rac-18 could not be separated by column chromatography and were characterized as mixtures of diastereomers. The diastereomeric ratios of compounds 17/rac-17 and 18/rac-18 were determined using proton spectra, in which the non-overlapping signals were integrated. Similarly, the keto–enol ratios of compounds 2, 10, 11, 17/rac-17, and 20 were determined from proton spectra. β-Keto esters 2, 10, and 17/rac-17 contain up to 17% (17% for compound 2i, see ESI) of the enol form, as indicated by the enol signal in the proton spectra (a singlet) at approximately 11.5–13.5 ppm. For details, see the ESI. In contrast, the enol form is the predominant tautomer for the pyrrolones 11a–c in DMSO-d₆ (ranging from 55% for 11a′ to 63% for 11b′; see Scheme 2) [22,23]. The tetronic acid derivative 20 exists in CDCl₃ solution exclusively in the enol form, as indicated by the enol-ester resonances in the ¹³C NMR spectra at 99.1 ppm, 177.4 ppm, and 177.9 ppm, and by the absence of a ketone signal above 200 ppm (see Scheme 5 and the ESI). The (E) configuration around the C=C bond of compound 16 was assigned based on the vicinal RHC=CHNO₂ coupling constant (³J = 13.4 Hz). The structure and (1S,2S)-absolute configuration of the stereoisomer of adduct 17a (prepared with organocatalyst I) were determined by single-crystal X-ray diffraction analysis (Figure 1). The (1S)-absolute configuration is consistent with our previous findings [21]. Based on this, we assigned the (1R)-absolute configuration to the major enantiomer of both diastereomers of products 17a, 17b, 17d, 17f, 17h, 17j, and 17l prepared with organocatalyst VIII; the results are fully consistent with the stereochemistry findings of the seminal paper by Viresh H. Rawal, who first prepared and applied organocatalyst VIII in the Michael addition of 1,3-dicarbonyl nucleophiles to trans-β-nitrostyrene acceptors [57]. The absolute configuration at the C-2 chiral center is labile due to rapid keto–enol tautomerization. The (1′S,5S)-absolute configuration of the major diastereomer of product 18a (see Scheme 5) was assigned based on our previous results in the series of 1,4-adducts of pyrrolones to nitroalkene acceptors [23].

Figure 1. Molecular structure of the (1S,2S)-stereoisomer of product 17a, synthesized using catalyst I. Thermal ellipsoids are shown at 50% probability.

Proposed mechanism for the 1,4-addition of β-keto esters. Possible transition-state variants of the bifunctional mechanisms of cinchona-derived squaramide and thiourea organocatalysts have been studied previously. The proposed transition states are based on literature data for similar reactions and on the absolute configuration of product 17a. Since the formation of product 17a with organocatalyst VIII must occur through Re face attack of β-keto ester 2a on trans-β-nitrostyrene (12), two possible transition states are proposed (Figure 2). The difference between the two transition states lies in the mode of activation. In Model A, proposed by Takemoto et al., the nucleophile is directed by the amine group, while the electrophile is activated by the squaramide NH [58]. In Model B, proposed by Pápai et al., the nucleophile is directed by the squaramide NH, and the electrophile is activated by the protonated amine group [59,60,61]. The orientation of the nucleophile is irrelevant, as it determines only the absolute configuration at the epimerizable C-2 stereocenter.

Figure 2. Two possible transition state models for the asymmetric Michael addition reaction 2a + 12 → 17a, based on the absolute configuration of product 17a.

3. Materials and Methods

Solvents for extractions and chromatography were of technical grade and were distilled prior to use. Extracts were dried over technical grade anhydrous Na₂SO₄. Melting points were determined on a Kofler micro hot stage and on SRS OptiMelt MPA100—Automated Melting Point System (Stanford Research Systems, Sunnyvale, CA, USA). The NMR spectra were obtained on a Bruker UltraShield 500 plus spectrometer and on a BRUKER AVANCE NEO 600 MHz NMR spectrometer (Bruker, Billerica, MA, USA) at 500 and 600 MHz for ¹H and 126 and 150 MHz for ¹³C nuclei, respectively, using DMSO-d₆ and CDCl₃ with TMS as the internal standard, as solvents. Mass spectra were recorded on an Agilent 6224 Accurate Mass TOF LC/MS and Agilent 6530 Q-TOF LC/MS coupled with Agilent 1260 Infinity2 HPLC (Agilent Technologies, Santa Clara, CA, USA), IR spectra on a Perkin-Elmer Spectrum BX FTIR spectrophotometer (PerkinElmer, Waltham, MA, USA). Column chromatography (CC) was performed on silica gel (Silica gel 60, particle size: 0.035–0.070 mm (Sigma-Aldrich, St. Louis, MO, USA)). HPLC analyses were performed on an Agilent 1260 Infinity LC (Agilent Technologies, Santa Clara, CA, USA) using CHIRALPAK IA-3 (0.46 cm ø × 25 cm), CHIRALPAK AD-H (0.46 cm ø × 25 cm), CHIRALCEL OD-H (0.46 cm ø × 25 cm), and CHIRALPAK AS-H (0.46 cm ø × 25 cm) as chiral column (CHIRAL TECHNOLOGIES, INC., West Chester, PA, USA). All the commercially available chemicals used were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Organocatalysts I [21], II [62], III [63], IV [63], VI [64], VII [65], VIII [57], and IX [66] were prepared following the literature procedures; organocatalyst V was purchased from Sigma-Aldrich.

3.1. Synthesis of β-Keto Esters 2 from Carboxylic Acids 1—General Procedure 1 (GP1)

To a solution or suspension of carboxylic acid 1 (10 mmol) in anhydrous THF (50 mL), 1,1′-carbonyldiimidazole (CDI; 12 mmol, ω = 0.97, 1.672 g) was added under argon, and the resulting reaction mixture was stirred for 2 h at room temperature. A solid mixture of MgCl₂ (9.8 mmol, ω = 0.98, 952 mg) and methyl potassium malonate (15 mmol, 2.343 g) or tert-butyl potassium malonate (15 mmol, ω = 0.95, 3.130 g) was then added. The reaction mixture was stirred for a further 24 h under argon at room temperature. The volatiles were evaporated in vacuo, the residue was dissolved in EtOAc (150 mL) and washed with NaHSO₄ (1 M in H₂O, 3 × 50 mL), NaHCO₃ (aq. sat., 2 × 20 mL), and NaCl (aq. sat., 2 × 50 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and the volatiles evaporated in vacuo. If necessary, the residue was purified by column chromatography (CC, Silica gel 60). The fractions containing the product were combined, and the volatiles were evaporated in vacuo.

3.2. Synthesis of Methyl 4-((Tert-butoxycarbonyl)amino)-3-oxobutanoate (2a) [22]

Following GP1, prepared from (tert-butoxycarbonyl)glycine (1a) (10 mmol, 1.752 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 2.10 g (9.1 mmol, 91%) of yellowish oil. ¹H-NMR (500 MHz, DMSO-d₆): δ 1.39 (s, 9H), 3.60 (s, 2H), 3.63 (s, 3H), 3.86 (d, J = 5.9 Hz, 2H), 7.13 (t, J = 5.9 Hz, 1H). ¹³C-NMR (126 MHz, DMSO-d₆): δ 28.18, 45.91, 49.81, 51.93, 78.30, 155.81, 167.50, 200.67.

3.3. Synthesis of Methyl 5-((Tert-butoxycarbonyl)amino)-3-oxopentanoate (2b) [22]

Following GP1, prepared from Boc-β-alanine (1b) (10 mmol, 1.892 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 2.18 g (8.9 mmol, 89%) of yellowish oil. ¹H-NMR (500 MHz, DMSO-d₆): δ 1.36 (s, 9H), 2.66 (t, J = 6.9 Hz, 2H), 3.11 (q, J = 6.9 Hz, 2H), 3.61 (s, 2H), 3.62 (s, 3H), 6.77 (t, J = 5.6 Hz, 1H). ¹³C-NMR (126 MHz, DMSO-d₆): δ 28.24, 34.88, 42.40, 48.68, 51.84, 77.72, 155.53, 167.71, 202.42.

3.4. Synthesis of Methyl 4-((3-Methylbut-2-en-1-yl)oxy)-3-oxobutanoate (2c) [67]

Following GP1, prepared from 2-((3-methylbut-2-en-1-yl)oxy)acetic acid (1c) [68] (10 mmol, 1.442 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 1.602 g (8.0 mmol, 80%) of colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 1.69 (s, 3H), 1.77 (s, 3H), 3.55 (s, 2H), 3.74 (s, 3H), 4.04 (d, J = 7.1 Hz, 2H), 4.09 (s, 2H), 5.29–5.36 (m, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 18.11, 25.88, 45.77, 52.41, 67.89, 74.63, 119.97, 138.70, 167.62, 202.30.

3.5. Synthesis of Methyl 3-Oxooctadecanoate (2d) [69]

Following GP1, prepared from palmitic acid (1d) (10 mmol, 2.564 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction and column chromatography (EtOAc/petroleum ether = 1:10). Yield: 2717 g (8.70 mmol, 87%) of white solid; m.p. = 49.2–50.5 °C. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.19–1.35 (m, 24H), 1.53–1.65 (m, 2H), 2.53 (t, J = 7.4 Hz, 2H), 3.45 (s, 2H), 3.74 (s, 3H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.26, 22.83, 23.60, 29.14, 29.49, 29.50, 29.58, 29.73, 29.77, 29.79, 29.80, 29.82, 29.83, 32.06, 43.23, 49.15, 52.46, 167.85, 203.01.

3.6. Synthesis of Methyl 3-Oxoicosanoate (2e) [69]

Following GP1, prepared from stearic acid (1e) (10 mmol, 2.845 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction and column chromatography (EtOAc/petroleum ether = 1:10). Yield: 2.282 g (6.70 mmol, 67%) of white solid; m.p. = 49.5–51.2 °C. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.18–1.34 (m, 28H), 1.55–1.63 (m, 2H), 2.53 (t, J = 7.4 Hz, 2H), 3.45 (s, 2H), 3.74 (s, 3H). ¹³C-NMR (151 MHz, CDCl₃): δ 14.25, 22.83, 23.60, 29.14, 29.49, 29.50, 29.58, 29.73, 29.78, 29.79, 29.80, 29.83, 32.06, 43.22, 49.14, 52.45, 167.84, 203.00 (3 signals missing due to overlapping).

3.7. Synthesis of Tert-Butyl 3-Oxoicosanoate (2f)

Following GP1, prepared from stearic acid (1e) (10 mmol, 2.845 g), tert-butyl potassium malonate (15 mmol, ω = 0.95, 3.130 g); isolation by extraction and column chromatography (EtOAc/petroleum ether = 1:15). Yield: 1.722 g (4.50 mmol, 45%) of white solid; m.p. = 36.9–38.1 °C. EI-HRMS: m/z = 327.2885 (MH⁺-tBuOH); C₂₀H₃₉O₃ requires m/z = 327.2894 (MH⁺-tBuOH); ν_max 2960, 2916, 2849, 1729, 1715, 1466, 1406, 1367, 1329, 1276, 1260, 1155, 1131, 1109, 1080, 947, 920, 842, 790, 723, 647 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.21–1.34 (m, 28H), 1.47 (s, 9H), 1.55–1.61 (m, 2H), 2.51 (t, J = 7.4 Hz, 2H), 3.34 (s, 2H). ¹³C-NMR (151 MHz, CDCl₃): δ 14.26, 22.83, 23.62, 28.10, 29.21, 29.50, 29.52, 29.59, 29.74, 29.78, 29.80, 29.81, 29.84, 32.07, 43.09, 50.81, 81.99, 166.69, 203.68 (3 signals missing due to overlapping).

3.8. Synthesis of Methyl (11Z,14Z)-3-Oxoicosa-11,14-dienoate (2g) [69]

Following GP1, prepared from linoleic acid (1f) (10 mmol, 2.804 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction and column chromatography (EtOAc/petroleum ether = 1:5). Yield: 1.851 g (5.50 mmol, 55%) of colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 0.89 (t, J = 6.9 Hz, 3H), 1.23–1.40 (m, 14H), 1.54–1.64 (m, 2H), 1.97–2.09 (m, 4H), 2.53 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 6.6 Hz, 2H), 3.45 (s, 2H), 3.74 (s, 3H), 5.28–5.43 (m, 4H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.21, 22.71, 23.57, 25.76, 27.31, 27.33, 29.10, 29.21, 29.39, 29.48, 29.72, 31.66, 43.20, 49.15, 52.46, 128.02, 128.19, 130.15, 130.35, 167.83, 202.95.

3.9. Synthesis of Methyl (S)-4-((Tert-butoxycarbonyl)amino)-3-oxo-5-phenylpentanoate (10a) [22]

Following GP1, prepared from Boc-L-phenylalanine (9a) (10 mmol, 2.653 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 2.346 g (7.30 mmol, 73%) of colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 1.40 (s, 9H), 2.98 (dd, J = 7.5, 14.1 Hz, 1H), 3.14 (dd, J = 6.2, 14.1 Hz, 1H), 3.46 (d, J = 16.0 Hz, 1H), 3.52 (d, J = 16.0 Hz, 1H), 3.71 (s, 3H), 4.56 (q, J = 7.2 Hz, 1H), 4.96–5.07 (m, 1H), 7.14–7.20 (m, 2H), 7.21–7.35 (m, 3H).

3.10. Synthesis of Methyl (S)-8-(((Benzyloxy)carbonyl)amino)-4-((tert-butoxycarbonyl)amino)-3-oxooctanoate (10b) [22]

Following GP1, prepared from Boc-Lys(Z)-OH (9b) (10 mmol, 3.804 g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 3.317 g (7.60 mmol, 76%) of colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 1.30–1.65 (m, 5H), 1.43 (s, 9H), 1.81–1.93 (m, 1H), 3.12–3.27 (m, 2H), 3.54 (d, J = 15.7 Hz, 1H), 3.59 (d, J = 16.0 Hz, 1H), 3.73 (s, 3H), 4.27–4.36 (m, 1H), 4.93 (t, J = 6.0 Hz, 1H), 5.05–5.17 (m, 2H), 5.27 (br d, J = 7.7 Hz, 1H), 7.28–7.39 (m, 5H).

3.11. Synthesis of 7-Benzyl 1-Methyl (S)-4-((Tert-butoxycarbonyl)amino)-3-oxoheptanedioate (10c) [23]

Following GP1, prepared from Boc-Glu(OBzl)-OH (9c) (10 mmol, 3.374g), methyl potassium malonate (15 mmol, 2.343 g); isolation by extraction. Yield: 2.675 g (6.80 mmol, 68%) of colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 1.43 (s, 9H), 1.80–1.91 (m, 1H), 2.22–2.32 (m, 1H), 2.38–2.56 (m, 2H), 3.55–3.65 (m, 2H), 3.73 (s, 3H), 4.38–4.45 (m, 1H), 5.12 (s, 2H), 5.23 (br d, J = 8.1 Hz, 1H), 7.29–7.41 (m, 5H).

3.12. Synthesis of Methyl (S)-5-((Tert-butoxycarbonyl)amino)-2-stearamidopentanoate (4)

To a solution of stearic acid (1e) (20 mmol, 5.690 g) in anhydrous THF (50 mL) was added 1,1′-carbonyldiimidazole (CDI; 22 mmol, ω = 0.97, 3.678 g) under argon, and the resulting reaction mixture was stirred for 2 h at room temperature. Then, H-Orn(Boc)-OMe×HCl (3) (22 mmol, ω = 0.96, 6.480 g) and Et₃N (22 mmol, 3.07 mL) were added. The reaction mixture was stirred for a further 24 h under argon at room temperature. The volatiles were evaporated in vacuo; the residue was dissolved in CH₂Cl₂ (150 mL) and washed with NaHSO₄ (1 M in H₂O, 4 × 50 mL), NaHCO₃ (aq. sat., 3 × 20 mL) and NaCl (aq. sat., 2 × 50 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and the volatiles evaporated in vacuo. Yield: 7.076 g (13.8 mmol, 69%) of white solid; m.p. = 86.0–88.0 °C. EI-HRMS: m/z = 513.4272 (MH⁺); C₂₉H₅₇N₂O₅ requires m/z = 513.4262 (MH⁺); ν_max 3345, 2915, 2847, 1762, 1684, 1648, 1526, 1473, 1462, 1369, 1285, 1252, 1212, 1171, 1143, 1047, 994, 950, 871, 754, 729, 719, 654 cm⁻¹. ¹H-NMR (500 MHz, DMSO-d₆): δ 0.85 (t, J = 6.8 Hz, 3H), 1.14–1.31 (m, 30H), 1.37 (s, 9H), 1.42–1.57 (m, 3H), 1.61–1.69 (m, 1H), 2.09 (t, J = 7.1 Hz, 2H), 2.89 (q, J = 6.8 Hz, 2H), 3.60 (s, 3H), 4.14–4.23 (m, 1H), 6.79 (t, J = 5.7 Hz, 1H), 8.14 (d, J = 7.5 Hz, 1H). ¹³C-NMR (126 MHz, DMSO-d₆): δ 13.98, 22.11, 25.23, 26.02, 28.20, 28.26, 28.55, 28.72, 28.78, 28.97, 29.02, 29.05, 31.31, 34.94, 51.65, 51.70, 77.40, 155.58, 172.43, 172.78 (7 signals missing due to overlapping).

3.13. Synthesis of (S)-5-((Tert-butoxycarbonyl)amino)-2-stearamidopentanoic Acid (5)

To a solution/suspension of methyl (S)-5-((tert-butoxycarbonyl)amino)-2-stearamidopentanoate (4) (1.70 mmol, 872 mg) in a mixture of H₂O (3.0 mL) and THF (3.0 mL) was added NaOH (15.0 mmol, 600 mg). The reaction mixture was stirred for 3 h at room temperature. The mixture was acidified with HCl (aq. 1 M) to pH < 3 and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over Na₂SO₄, filtered and the volatiles evaporated in vacuo. The residue was azeotropically evaporated with CHCl₃ (3 × 30 mL) to give the anhydrous product 5. Yield: 763 mg (1.53 mmol, 90%) of white solid; m.p. = 82.0–84.3 °C. EI-HRMS: m/z = 499.4113 (MH⁺); C₂₈H₅₅N₂O₅ requires m/z = 499.4105 (MH⁺); ν_max 3359, 2955, 2916, 2849, 1738, 1682, 1605, 1525, 1465, 1454, 1388, 1365, 1290, 1274, 1244, 1210, 1170, 1112, 1043, 1019, 957, 890, 860, 783, 727, 637 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.17–1.36 (m, 28H), 1.44 (s, 9H), 1.52–1.67 (m, 4H), 1.68–1.79 (m, 1H), 1.87–1.98 (m, 1H), 2.25 (t, J = 7.8 Hz, 2H), 3.04–3.27 (m, 2H), 4.60 (td, J = 4.9, 7.5 Hz, 1H), 4.86 (t, J = 6.4 Hz, 1H), 6.73 (br d, J = 7.4 Hz, 1H), 9.64 (br s, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.27, 22.84, 25.79, 26.56, 28.52, 29.06, 29.42, 29.49, 29.51, 29.67, 29.80, 29.83, 29.86, 32.07, 36.57, 39.88, 52.22, 79.99, 156.91, 174.55, 174.80 (5 signals missing due to overlapping). ¹H-NMR (500 MHz, DMSO-d₆): δ 0.85 (t, J = 6.9 Hz, 3H), 1.06–1.31 (m, 29H), 1.37 (s, 9H), 1.32–1.56 (m, 4H), 1.61–1.71 (m, 1H), 2.04–2.15 (m, 2H), 2.84–2.94 (m, 2H), 4.13 (td, J = 5.0, 8.5 Hz, 1H), 6.77 (t, J = 5.8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 12.40 (br s, 1H). ¹³C-NMR (126 MHz, DMSO-d₆): δ 13.91, 22.06, 25.24, 26.15, 28.23, 28.43, 28.57, 28.66, 28.77, 28.93, 28.97, 29.00, 31.26, 35.02, 51.54, 77.33, 155.54, 172.23, 173.71 (7 signals missing due to overlapping).

3.14. Synthesis of Methyl (S)-7-((Tert-butoxycarbonyl)amino)-3-oxo-4-stearamidoheptanoate (2h)

Following GP1, prepared from (S)-5-((tert-butoxycarbonyl)amino)-2-stearamidopentanoic acid (5) (1.5 mmol, 748 mg), CDI (1.8 mmol, ω = 0.97, 301 mg), MgCl₂ (1.47 mmol, ω = 0.98, 143 mg), methyl potassium malonate (2.25 mmol, 351 mg); isolation by extraction and column chromatography (EtOAc/petroleum ether = 1:1). Yield: 591 mg (1.065 mmol, 71%) of white solid; m.p. = 62.3–64.9 °C. EI-HRMS: m/z = 555.4384 (MH⁺); C₃₁H₅₉N₂O₆ requires m/z = 555.4368 (MH⁺); ν_max 3341, 2915, 2848, 1747, 1711, 1681, 1638, 1524, 1438, 1390, 1365, 1316, 1251, 1168, 1016, 886, 769, 719, 643 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.18–1.35 (m, 28H), 1.44 (s, 9H), 1.47–1.68 (m, 5H), 1.90–2.00 (m, 1H), 2.21–2.26 (m, 2H), 3.15 (q, J = 6.7 Hz, 2H), 3.58 (s, 2H), 3.74 (s, 3H), 4.66 (br s, 1H), 4.68–4.74 (m, 1H), 6.43 (br d, J = 7.4 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.27, 22.83, 25.73, 26.44, 27.58, 28.52, 29.44, 29.47, 29.50, 29.63, 29.77, 29.80, 29.84, 32.06, 36.62, 39.87, 46.26, 52.66, 58.11, 79.56, 156.40, 167.45, 173.54, 201.86 (6 signals missing due to overlapping). ¹H-NMR (500 MHz, DMSO-d₆): δ 0.85 (t, J = 6.9 Hz, 3H), 1.08–1.30 (m, 29H), 1.37 (s, 9H), 1.31–1.54 (m, 4H), 1.62–1.75 (m, 1H), 2.12 (t, J = 7.4 Hz, 2H), 2.89 (q, J = 6.2 Hz, 2H), 3.58 (s, 2H), 3.61 (s, 3H), 4.23 (ddd, J = 4.5, 7.3, 9.5 Hz, 1H), 6.78 (t, J = 5.9 Hz, 1H), 8.16 (d, J = 7.4 Hz, 1H). ¹³C-NMR (126 MHz, DMSO-d₆): δ 13.90, 22.05, 25.10, 25.88, 26.25, 28.22, 28.57, 28.65, 28.71, 28.89, 28.96, 28.99, 31.25, 34.91, 45.49, 51.76, 57.75, 77.36, 155.57, 167.46, 172.67, 202.73 (7 signals missing due to overlapping).

3.15. Synthesis of (S)-5-Methoxy-5-oxo-4-stearamidopentan-1-aminium 2,2,2-Trifluoroacetate (6)

Methyl (S)-5-((tert-butoxycarbonyl)amino)-2-stearamidopentanoate (4) (10 mmol, 5.128 g) was dissolved in a 1:1 mixture of CF₃COOH and anhydrous CH₂Cl₂ (60 mL) under argon, and the reaction mixture was stirred for 3 h at room temperature. Volatile components were evaporated in vacuo, and the residue was azeotropically evaporated with anhydrous toluene (3 × 100 mL) to give ammonium salt 6. Yield: 5.00 g (9.50 mmol, 95%) of white solid; m.p. = 93.0–95.7 °C. EI-HRMS: m/z = 413.3726 (MH⁺); C₂₄H₄₉N₂O₃⁺ requires m/z = 413.3738 (MH⁺); ν_max 3318, 2915, 2848, 1752, 1671, 1645, 1528, 1474, 1462, 1430, 1400, 1381, 1358, 1276, 1237, 1207, 1173, 1127, 1067, 1003, 970, 955, 893, 839, 800, 768, 747, 723, 668, 613 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 0.88 (t, J = 6.9 Hz, 3H), 1.09–1.35 (m, 26H), 1.53–1.63 (m, 2H), 1.69–1.85 (m, 3H), 1.91–2.01 (m, 1H), 2.23–2.33 (m, 2H), 3.01–3.20 (m, 2H), 3.76 (s, 3H), 4.48–4.57 (m, 1H), 6.86 (d, J = 7.5 Hz, 1H), 7.61 (br s, 3H). ¹³C-NMR (126 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 14.25, 22.84, 23.37, 25.78, 29.22, 29.28, 29.31, 29.51, 29.59, 29.74, 29.80, 29.81, 29.86, 32.07, 36.22, 39.62, 51.65, 53.08, 115.46 (q, J = 287.8 Hz), 161.08 (q, J = 39.3 Hz), 172.10, 176.30 (3 signals missing due to overlapping).

3.16. Synthesis of Methyl (S)-2,5-Distearamidopentanoate (7)

To a solution of stearic acid (1e) (8.5 mmol, 2.416 g) in anhydrous THF (30 mL), 1,1′-carbonyldiimidazole (CDI; 9.35 mmol, ω = 0.97, 1.563 g) was added under argon, and the resulting reaction mixture was stirred for 2 h at room temperature. The resulting activated acid was transferred to a suspension of (S)-5-methoxy-5-oxo-4-stearamidopentan-1-aminium 2,2,2-trifluoroacetate (6) (9.35 mmol, 4.924 g) in anhydrous THF (30 mL) under argon. Et₃N (9.35 mmol, 1.303 mL) was then added to the reaction mixture at room temperature. The reaction mixture was stirred at 40 °C for 12 h. Volatile components were evaporated in vacuo. The residue was extracted with CH₂Cl₂ (100 mL), EtOAc (100 mL), Et₂O (100 mL), and n-hexane (100 mL) using a laboratory ultrasonic bath (5 min each), followed by decanting, respectively, to remove unreacted starting material and small portions of the product. H₂O (150 mL) was added to the residue, followed by ultrasonic bath treatment (15 min). The resulting precipitate was collected by filtration and thoroughly washed with H₂O (3 × 70 mL). The residue was dried under high vacuum at 40 °C for 12 h to give product 7. Yield: 3.476 g (5.270 mmol, 62%) of white solid; m.p. = 106.7–108.4 °C. EI-HRMS: m/z = 679.6336 (MH⁺); C₄₂H₈₃N₂O₄ requires m/z = 679.6347 (MH⁺); ν_max 3305, 2914, 2848, 1742, 1639, 1542, 1470, 1420, 1385, 1277, 1259, 1239, 1205, 1173, 980, 717 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 0.88 (t, J = 6.9 Hz, 6H), 1.18–1.36 (m, 56H), 1.54–1.77 (m, 7H), 1.87–1.97 (m, 1H), 2.26–2.38 (m, 4H), 3.23–3.34 (m, 1H), 3.34–3.47 (m, 1H), 3.79 (s, 3H), 4.57–4.64 (m, 1H), 6.70 (t, J = 6.1 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 14.25, 22.84, 24.97, 25.87, 25.99, 29.20, 29.23, 29.28, 29.51, 29.56, 29.72, 29.78, 29.81, 29.83, 29.85, 30.00, 32.07, 36.28, 36.35, 39.58, 52.17, 53.15, 172.43, 176.50, 177.11 (17 signals missing due to overlapping).

3.17. Synthesis of (S)-2,5-Distearamidopentanoic Acid (8)

To a suspension of methyl (S)-2,5-distearamidopentanoate (7) (5 mmol, 3.393 g) in a mixture of H₂O (20 mL) and THF (5 mL), KOH (powder for synthesis, 50 mmol, 2.810 g) was added, and the reaction mixture was stirred at 90 °C for 12 h. The mixture was cooled to room temperature, and HCl (aq., 2 M) was added under stirring until the pH reached 1–2. The precipitate was collected by filtration and thoroughly washed with H₂O (3 × 100 mL). The residue was dried under high vacuum at 40 °C for 12 h to give acid 8. Yield: 2.792 g (4.20 mmol, 84%) of white solid; m.p. = 108.8–110.1 °C. EI-HRMS: m/z = 665.6191 (MH⁺); C₄₁H₈₁N₂O₄ requires m/z = 665.6191 (MH⁺); ν_max 3310, 2955, 2916, 2849, 1736, 1639, 1586, 1545, 1466, 1446, 1418, 1372, 1275, 1245, 1211, 1181, 1128, 970, 829, 720, 685, 633 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 0.88 (t, J = 6.8 Hz, 6H), 1.09–1.40 (m, 56H), 1.52–1.73 (m, 6H), 1.75–1.89 (m, 1H), 1.92–2.11 (m, 1H), 2.27–2.45 (m, 4H), 3.13–3.49 (m, 2H), 4.61 (q, J = 6.7, 1H), 6.87 (s, 1H), 6.98 (d, J = 7.3 Hz, 1H), 11.12 (br s, 1H). ¹³C-NMR (126 MHz, CDCl₃ (700 μL) + TFA (20 μL)): δ 14.26, 22.84, 24.97, 25.88, 25.96, 29.14, 29.19, 29.21, 29.25, 29.27, 29.52, 29.55, 29.57, 29.73, 29.79, 29.82, 29.84, 29.86, 32.08, 36.09, 36.13, 39.82, 52.36, 175.92, 177.30, 177.72 (15 signals missing due to overlapping).

3.18. Synthesis of Methyl (S)-3-Oxo-4,7-distearamidoheptanoate (2i)

To a suspension of (S)-2,5-distearamidopentanoic acid (8) (2.5 mmol, 1.662 g) in anhydrous THF (25 mL), 1,1′-carbonyldiimidazole (CDI; 5 mmol, ω = 0.97, 836 mg) was added under argon, and the reaction mixture was stirred for 15 min at room temperature, 30 min at 90 °C, and 60 min at 50 °C. Then, a solid mixture of MgCl₂ (2.5 mmol, ω = 0.98, 243 mg) and methyl potassium malonate (7.5 mmol, 1.171 g) was carefully added at 50 °C. The reaction mixture was stirred for 15 min at 50 °C, 30 min at 90 °C, and 24 h at room temperature. The volatiles were evaporated in vacuo, and NaHSO₄ (1 M in H₂O, 100 mL) was added to the residue. The mixture was stirred at room temperature for 30 min. The precipitate was collected by filtration and thoroughly washed with H₂O (3 × 100 mL). The residue was dried under high vacuum at 40 °C for 12 h to give β-keto ester 2i. Yield: 1.099 g (1.525 mmol, 61%) of white solid; m.p. = 92.1–94.7 °C. EI-HRMS: m/z = 721.6456 (MH⁺); C₄₄H₈₅N₂O₅ requires m/z = 721.6453 (MH⁺); ν_max 3306, 2916, 2849, 1748, 1717, 1638, 1539, 1463, 1378, 1328, 1258, 1239, 1223, 1204, 1147, 1013, 719 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 6H), 1.18–1.39 (m, 56H), 1.51–1.67 (m, 7H), 1.88–1.97 (m, 1H), 2.17 (t, J = 7.7 Hz, 2H), 2.25 (t, J = 7.7 Hz, 2H), 3.22–3.38 (m, 2H), 3.58 (d, J = 1.7 Hz, 2H), 3.74 (s, 3H), 4.65–4.72 (m, 1H), 5.87 (t, J = 6.0 Hz, 1H), 6.67 (d, J = 7.5 Hz, 1H). ¹³C-NMR (151 MHz, CDCl₃): δ 14.26, 22.83, 25.72, 25.94, 25.98, 27.70, 29.45, 29.50, 29.52, 29.66, 29.78, 29.80, 29.81, 29.85, 32.07, 36.56, 36.96, 38.86, 46.22, 52.66, 58.21, 167.58, 173.81, 173.95, 201.90 (19 signals missing due to overlapping).

3.19. Synthesis of Pyrrolones 11 from β-Keto Esters 10—General Procedure 2 (GP2)

To a solution of β-keto ester 10 (1.0 mmol) in anhydrous toluene (5 mL), DMFDMA (3 mmol, ω = 0.94, 424 μL) was added under argon and the resulting reaction mixture was stirred at 70 °C under argon until completion of the reaction, as judged by TLC analysis (1–3 h). The volatiles were evaporated in vacuo, and the residue was purified as quickly as possible by column chromatography (CC, Silica gel 60). The fractions containing the product 11 were combined, and the volatiles were evaporated in vacuo. The product was immediately used for the following transformation and/or stored under argon at −20 °C.

3.20. Synthesis of 1-(Tert-butyl) 3-Methyl 5-Benzyl-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11a) and 1-(Tert-butyl) 3-Methyl 5-Benzyl-4-hydroxy-1H-pyrrole-1,3-dicarboxylate (11a′) [22]

Following GP2, prepared from methyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxo-5-phenylpentanoate (10a) (1 mmol, 321.4 mg), 45 min; CC (EtOAc/petroleum ether = 1:1). 11a/11a′ = 45:55 (in DMSO-d₆). Yield: 268 mg (0.81 mmol, 81%) of colorless oil. ¹H-NMR (500 MHz, DMSO-d₆) for 11a: δ 1.55 (s, 9H), 3.22 (dd, J = 2.7, 13.8 Hz, 1H), 3.38 (dd, J = 6.4, 13.8 Hz, 1H), 3.61 (s, 3H), 4.58 (dd, J = 2.6, 6.3 Hz, 1H), 6.91–6.97 (m, 2H), 8.71 (s, 1H). ¹H-NMR (500 MHz, DMSO-d₆) for 11a′: δ 1.34 (s, 9H), 3.76 (s, 3H), 4.14 (s, 2H), 6.98–7.04 (m, 2H), 7.11–7.28 (m, 3H), 7.57 (s, 1H), 8.26 (s, 1H).

3.21. Synthesis of 1-(Tert-butyl) 3-Methyl 5-(4-(((Benzyloxy)carbonyl)amino)butyl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11b) and 1-(Tert-butyl) 3-Methyl 5-(4-(((Benzyloxy)carbonyl)amino)butyl)-4-hydroxy-1H-pyrrole-1,3-dicarboxylate (11b′) [22]

Following GP2, prepared from methyl (S)-8-(((benzyloxy)carbonyl)amino)-4-((tert-butoxycarbonyl)amino)-3-oxooctanoate (10b) (1 mmol, 436.5 mg), 1 h; CC (EtOAc/petroleum ether = 1:1). 11b/11b′ = 37:63 (in DMSO-d₆). Yield: 336 mg (0.82 mmol, 82%) of colorless oil. ¹H-NMR (500 MHz, DMSO-d₆) for 11b: δ 0.98–1.08 (m, 1H), 1.08–1.19 (m, 1H), 1.50 (s, 9H), 1.83–1.93 (m, 1H), 1.97–2.08 (m, 1H), 2.93 (q, J = 6.7 Hz, 2H), 3.68 (s, 3H), 4.30 (dd, J = 3.1, 6.5 Hz, 1H), 8.98 (s, 1H). ¹H-NMR (500 MHz, DMSO-d₆) for 11b′: δ 1.28–1.46 (m, 4H), 1.54 (s, 9H), 2.70 (t, J = 6.9 Hz, 2H), 2.98 (q, J = 6.3 Hz, 2H), 3.73 (s, 3H), 4.99 (s, 2H), 7.23 (t, J = 5.8 Hz, 1H), 7.26–7.41 (m, 5H), 7.49 (s, 1H), 7.95 (s, 1H).

3.22. Synthesis of 1-(Tert-butyl) 3-Methyl 5-(3-(Benzyloxy)-3-oxopropyl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11c) and 1-(Tert-butyl) 3-Methyl 5-(3-(Benzyloxy)-3-oxopropyl)-4-hydroxy-1H-pyrrole-1,3-dicarboxylate (11c′) [23]

Following GP2, prepared from 7-benzyl 1-methyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxoheptanedioate (10c) (1 mmol, 393.4 mg), 45 min; CC (EtOAc/petroleum ether = 1:1). 11c/11c′ = 42:58 (in DMSO-d₆). Yield: 343 mg (0.85 mmol, 85%) of colorless oil. ¹H-NMR (500 MHz, DMSO-d₆) for 11c: δ 1.50 (s, 9H), 3.68 (s, 3H), 4.35–4.40 (m, 1H), 5.06 (d, J = 5.4 Hz, 2H), 8.92 (s, 1H). ¹H-NMR (500 MHz, DMSO-d₆) for 11c′: δ 1.53 (s, 9H), 2.51–2.57 (m, 2H), 2.99–3.05 (m, 2H), 3.73 (s, 3H), 5.08 (s, 2H), 7.30–7.40 (m, 5H), 7.49 (s, 1H), 8.11 (s, 1H).

3.23. Synthesis of Hexadecan-1-ol (13) [54]

Palmitic acid (11d) (20 mmol, 5.128 g) was dissolved in anhydrous THF (80 mL) under argon, and the solution was cooled in an ice bath (0 °C). While stirring in the ice bath, LiAlH₄ (2.4 M in THF, 80 mmol, 33.3 mL) was added, and the reaction mixture was allowed to warm to room temperature over 1 h. The reaction mixture was stirred for a further 24 h under argon at room temperature and then quenched by careful addition of NaOH (1 M in H₂O, 60 mL). The reaction mixture was extracted with diethyl ether (2 × 70 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and the volatile components evaporated in vacuo. Yield: 3.957 g (16.3 mmol, 81%) of a white solid. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.19–1.39 (m, 27H), 1.52–1.61 (m, 2H), 3.64 (t, J = 6.6 Hz, 2H).

3.24. Synthesis of Palmitaldehyde (14) [55]

To a solution of hexadecan-1-ol (13) (16.3 mmol, 3.951 g) in anhydrous CH₂Cl₂ (100 mL), pyridinium chlorochromate (PCC, 24.5 mmol, ω = 0.98, 5.389 g) was added at room temperature and the reaction mixture was stirred for 16 h at room temperature. The solution was filtered through a plaque of Celite^®, washed with CH₂Cl₂ and the volatiles evaporated in vacuo. The residue was purified by column chromatography (Silica gel 60, petroleum ether/ethyl acetate = 10:1). The fractions containing the pure product 14 were combined and the volatile components were evaporated in vacuo. Yield: 2.940 g (12.23 mmol, 75%) of a colorless oil. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.26 (s, 24H), 1.58–1.67 (m, 2H), 2.42 (td, J = 1.9, 7.4 Hz, 2H), 9.76 (t, J = 1.9 Hz, 1H).

3.25. Synthesis of 1-Nitroheptadecan-2-ol (15)

This was prepared according to the literature procedure [56]. Palmitaldehyde (14) (11.44 mmol, 2.751 g) was dissolved in a mixture of anhydrous THF and anhydrous t-butanol in a 1:1 ratio (50 mL) under argon. Nitromethane (17.16 mmol, 930 μL) was then added at room temperature. The mixture was cooled to 0 °C, tBuOK (1.144 mmol, 128 mg) was added, and the reaction mixture was allowed to warm to room temperature over 1 h. After 16 h at room temperature under argon, the reaction mixture was diluted with H₂O (300 mL) and the product was extracted with diethyl ether (2 × 100 mL). The organic phase was washed with NaCl (aq. sat., 2 × 50 mL), dried over anhydrous Na₂SO₄, filtered, and the volatiles evaporated in vacuo. The crude product 15 was used for the following transformation without further purification. Yield: 2.794 g (9.267 mmol, 81%) of a yellowish oil. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.18–1.42 (m, 26H), 1.44–1.57 (m, 2H), 2.61 (br s, 1H), 4.28–4.34 (m, 1H), 4.38 (dd, J = 8.5, 13.0 Hz, 1H), 4.43 (dd, J = 2.7, 13.0 Hz, 1H).

3.26. Synthesis of (E)-1-Nitroheptadec-1-ene (16) [70]

This was prepared according to the literature procedure [56]. 1-Nitroheptadecan-2-ol (15) (9.12 mmol, 2.75 g) was dissolved in anhydrous CH₂Cl₂ (25 mL) and cooled to −10 °C. With stirring, trifluoroacetic anhydride (TFAA, 9.12 mmol, 1.269 mL) was added dropwise and the cooled mixture (−10 °C) was stirred for another 2 min. Over the next 10 min, triethylamine (2.532 mL, 18.24 mmol) was added dropwise and the reaction mixture was stirred at −10 °C for another 30 min. The reaction mixture was then diluted with CH₂Cl₂ (100 mL) and washed with NaHSO₄ (aq., 1 M, 200 mL). The aqueous phase was extracted with CH₂Cl₂ (2 × 40 mL). The combined organic phase was dried over anhydrous Na₂SO₄, filtered, and the volatiles evaporated in vacuo. The residue was purified by column chromatography (Silica gel 60; petroleum ether/EtOAc = 40:1). The fractions containing the pure product 16 were combined and the volatile components were evaporated in vacuo. Product 16 was stored under argon at 5 °C. Yield: 2.016 g (7.114 mmol, 78%) of a white solid; m.p. = 25.0–25.7 °C. EI-HRMS: m/z = 306.2395 (MNa⁺); C₁₇H₃₄NNaO₂ requires m/z = 306.2404 (MNa⁺); ν_max 2922, 2853, 1650, 1526, 1465, 1350, 960, 835, 723 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.19–1.37 (m, 24H), 1.51 (p, J = 7.3 Hz, 2H), 2.27 (qd, J = 1.5, 7.4 Hz, 2H), 6.98 (dt, J = 1.6, 13.4 Hz, 1H), 7.23–7.33 (m, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.27, 22.84, 27.86, 28.61, 29.24, 29.40, 29.51, 29.59, 29.72, 29.77, 29.80, 29.82, 29.84, 32.07, 139.69, 143.01 (1 signal missing due to overlapping).

3.27. Organocatalyzed Michael Addition of β-Keto Esters 2 to Nitroalkenes—General Procedure for the Preparation of Racemic Products rac-17—General Procedure 3 (GP3)

To a solution/suspension of nitroalkene 12 or 16 (0.2 mmol, 1.0 equivalent or 0.3 mmol, 1.5 equivalents) and the achiral organocatalyst X (0.04 mmol, 0.2 equivalents, 16.4 mg) in anhydrous CH₂Cl₂ (1 mL) under argon at room temperature, β-keto ester 2 (0.3 mmol, 1.5 equivalents or 0.2 mmol, 1.0 equivalent) was added, and the resulting reaction mixture was stirred at room temperature for 24–72 h. The volatiles were evaporated in vacuo, and the residue was purified by column chromatography (Silica gel 60, mobile phase). The fractions containing the pure racemic product rac-17 were combined, and the volatiles were evaporated in vacuo. The product rac-17 was fully characterized and analyzed by HPLC.

3.28. Organocatalyzed Michael Addition of β-Keto Esters 2 to Nitroalkenes—General Procedure for the Organocatalyzed Asymmetric Addition—General Procedure 4 (GP4)

To a solution/suspension of nitroalkene 12 or 16 (0.2 mmol, 1.0 equivalent or 0.3 mmol, 1.5 equivalents) and the chiral organocatalyst VIII (0.02 mmol, 0.1 equivalents, 12.3 mg) or I (0.02 mmol, 0.1 equivalents, 10.9 mg) in anhydrous CH₂Cl₂ (1 mL) under argon at room temperature, β-keto ester 2 (0.3 mmol, 1.5 equivalents or 0.2 mmol, 1.0 equivalent) was added, and the resulting reaction mixture was stirred at room temperature for 24–72 h. The volatiles were evaporated in vacuo, and the residue was purified by column chromatography (Silica gel 60, mobile phase). The fractions containing the pure chiral nonracemic product 17 were combined the volatiles were evaporated in vacuo. The product 17 was fully characterized and analyzed by HPLC.

3.29. Synthesis of Methyl 4-((Tert-butoxycarbonyl)amino)-2-((R)-2-nitro-1-phenylethyl)-3-oxobutanoate (17a)

Following GP3 and GP4, prepared from methyl 4-((tert-butoxycarbonyl)amino)-3-oxobutanoate (2a) (0.2 mmol, 46.3 mg) and trans-β-nitrostyrene (12) (0.3 mmol, 44.7 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:4). rac-17a Yield: 41.8 mg (0.110 mmol, 55%, two diastereomers in a ratio of 59:41 in DMSO-d₆) of white solid. 17a Yield: 63.9 mg (0.168 mmol, 84%, two diastereomers in a ratio of 56:44 in DMSO-d₆) of white solid; m.p. = 116–122 °C. EI-HRMS: m/z = 381.1641 (MH⁺); C₁₈H₂₅N₂O₇ requires m/z = 381.1656 (MH⁺); ν_max 3378, 2981, 1751, 1714, 1555, 1497, 1455, 1429, 1367, 1252, 1154, 1020, 974, 895, 858, 764, 699, 637 cm⁻¹. ¹H-NMR (500 MHz, DMSO-d₆) for major diastereomer: δ 1.39 (s, 9H), 3.37 (s, 3H), 3.95 (dd, J = 3.5, 5.8 Hz, 2H), 4.06–4.13 (m, 1H), 4.40 (d, J = 10.7 Hz, 1H), 4.87–4.96 (m, 2H), 7.18 (t, J = 5.9 Hz, 1H), 7.22–7.34 (m, 5H). ¹H-NMR (500 MHz, DMSO-d₆) for minor diastereomer: δ 1.33 (s, 9H), 3.70 (s, 3H), 3.50 (dd, J = 5.9, 18.8 Hz, 1H), 3.80 (dd, J = 5.8, 18.8 Hz, 1H), 4.46 (d, J = 10.2 Hz, 1H), 4.75 (dd, J = 4.3, 13.2 Hz, 1H), 4.85 (d, J = 10.8 Hz, 1H), 7.06 (t, J = 5.8 Hz, 1H). ¹³C-NMR (126 MHz, DMSO-d₆) for both diastereomers: δ 28.10, 28.14, 42.35, 42.65, 50.18, 50.25, 52.45, 52.84, 57.28, 57.93, 59.78, 77.74, 78.22, 78.24, 78.44, 127.79, 127.85, 128.18, 128.25, 128.49, 128.64, 136.85, 136.92, 155.47, 155.81, 167.33, 170.36, 199.88, 200.62 (3 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/i-PrOH = 80:20, flow rate 1.0 mL/min, λ = 210 nm, T = 20 °C. Diastereomer 1: tR = 9.24 min (minor); 17.62 min (major)—91% ee. Diastereomer 2: tR = 14.12 min (major); 23.56 min (minor)—93% ee.

3.30. Synthesis of Methyl 5-((Tert-butoxycarbonyl)amino)-2-((R)-2-nitro-1-phenylethyl)-3-oxopentanoate (17b) [22]

Following GP3 and GP4, prepared from methyl 5-((tert-butoxycarbonyl)amino)-3-oxopentanoate (2b) (0.2 mmol, 49.1 mg) and trans-β-nitrostyrene (12) (0.3 mmol, 44.7 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:4). rac-17b Yield: 69.4 mg (0.176 mmol, 88%, two diastereomers in a ratio of 53:47 in DMSO-d₆) of white solid. 17b Yield: 67.1 mg (0.170 mmol, 85%, two diastereomers in a ratio of 53:47 in DMSO-d₆) of white solid; m.p. = 96.1–98.4 °C. EI-HRMS: m/z = 417.1618 (MNa⁺); C₁₉H₂₇N₂NaO₇ requires m/z = 417.1632 (MNa⁺); ν_max 3424, 2978, 1743, 1707, 1553, 1506, 1455, 1434, 1366, 1246, 1164, 1082, 966, 859, 756, 701 cm⁻¹. ¹H-NMR (500 MHz, DMSO-d₆) for both diastereomers: δ 1.34 (s, 4.5H), 1.37 (s, 4.5H), 2.24–2.34 (m, 0.5H), 2.58–2.68 (m, 0.5H), 2.74 (t, J = 6.8 Hz, 1H), 2.76–2.91 (m, 1H), 3.15 (q, J = 6.4 Hz, 1H), 3.35 (s, 1.5H), 3.70 (s, 1.5H), 4.00–4.09 (m, 1H), 4.37 (dd, J = 6.0, 10.5 Hz, 1H), 4.81 (d, J = 7.5 Hz, 1H), 4.87–4.99 (m, 1H), 6.58 (t, J = 5.7 Hz, 0.5H), 6.85 (t, J = 5.7 Hz, 0.5H), 7.21–7.35 (m, 5H). ¹³C-NMR (126 MHz, DMSO-d₆) for both diastereomers: δ 28.19, 28.22, 34.52, 34.79, 42.30, 42.36, 42.66, 42.89, 52.43, 52.83, 60.00, 60.84, 77.69, 77.78, 78.00, 78.15, 127.79, 127.86, 128.27, 128.46, 128.63, 136.80, 136.96, 155.33, 155.53, 166.88, 167.72, 201.83 (6 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/i-PrOH = 80:20, flow rate 1.0 mL/min, λ = 210 nm, T = 20 °C. Diastereomer 1: tR = 7.22 min (minor); 8.98 min (major)—95% ee. Diastereomer 2: tR = 12.53 min (minor); 20.94 min (major)—95% ee.

3.31. Synthesis of Methyl 2-(3-((Tert-butoxycarbonyl)amino)propanoyl)-3-(nitromethyl)octadecanoate (rac-17c)

Following GP3, prepared from methyl 5-((tert-butoxycarbonyl)amino)-3-oxopentanoate (2b) (0.3 mmol, 73.6 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst X, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:5). rac-17c Yield: 55.0 mg (0.104 mmol, 52%, two diastereomers in a ratio of 53:47 in CDCl₃) of colorless oil. EI-HRMS: m/z = 429.3313 (MH⁺-Boc); C₂₃H₄₅N₂O₅ requires m/z = 429.3323 (MH⁺-Boc); ν_max 3413, 2923, 2853, 1743, 1712, 1552, 1505, 1436, 1366, 1248, 1168, 1084, 966, 911, 863, 781, 733 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃) for the major diastereomer: δ 0.88 (t, J = 6.9 Hz, 3H), 1.19–1.40 (m, 28H), 1.43 (s, 9H), 2.71–2.79 (m, 1H), 2.82–2.96 (m, 2H), 3.30–3.45 (m, 2H), 3.76 (s, 3H), 3.73–3.83 (m, 1H), 4.60 (dd, J = 5.0, 12.9 Hz, 1H), 4.65 (dd, J = 4.5, 13.2 Hz, 1H), 4.86–4.96 (m, 1H). ¹H-NMR (600 MHz, CDCl₃) for the minor diastereomer: δ 3.76 (s, 3H), 4.52 (dd, J = 5.9, 13.1 Hz, 2H). ¹³C-NMR (151 MHz, CDCl₃) for both diastereomers: δ 14.27, 22.83, 26.82, 26.88, 28.50, 29.42, 29.43, 29.49, 29.50, 29.63, 29.65, 29.74, 29.79, 29.81, 29.83, 29.84, 30.28, 32.06, 35.17, 36.64, 36.66, 43.35, 43.56, 52.94, 53.08, 59.31, 59.76, 76.02, 76.47, 79.58, 79.63, 155.95, 168.46, 203.83 (18 signals missing due to overlapping).

3.32. Synthesis of Methyl 4-((3-Methylbut-2-en-1-yl)oxy)-2-((R)-2-nitro-1-phenylethyl)-3-oxobutanoate (17d)

Following GP3 and GP4, prepared from methyl 4-((3-methylbut-2-en-1-yl)oxy)-3-oxobutanoate (2c) (0.2 mmol, 40.0 mg) and trans-β-nitrostyrene (12) (0.3 mmol, 44.7 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:5). rac-17d Yield: 54.5 mg (0.156 mmol, 78%, two diastereomers in a ratio of 60:40 in CDCl₃) of colorless oil. 17d Yield: 62.2 mg (0.178 mmol, 89%, two diastereomers in a ratio of 60:40 in CDCl₃) of colorless oil. EI-HRMS: m/z = 367.1858 (M+NH₄⁺); C₁₈H₂₇N₂O₆ requires m/z = 367.1864 (M+NH₄⁺); ν_max 3033, 2954, 2916, 1746, 1724, 1552, 1496, 1434, 1378, 1247, 1199, 1169, 1092, 1034, 981, 942, 893, 766, 700, 618 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for the major diastereomer: δ 1.61 (s, 3H), 1.74 (s, 3H), 3.73 (s, 3H), 3.76–3.90 (m, 2H), 4.21–4.32 (m, 3H), 4.79–4.95 (m, 3H), 5.20–5.24 (m, 1H), 7.18–7.24 (m, 2H), 7.25–7.33 (m, 3H). ¹H-NMR (500 MHz, CDCl₃) for the minor diastereomer: δ 1.66 (s, 3H), 1.75 (s, 3H), 3.52 (s, 3H), 3.98 (d, J = 7.0 Hz, 2H), 4.02 (d, J = 17.5 Hz, 1H), 4.10 (d, J = 17.4 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 18.12, 18.16, 25.90, 25.93, 42.13, 42.35, 52.80, 52.96, 56.60, 57.33, 67.75, 67.94, 74.72, 77.22, 77.77, 119.78, 119.80, 128.05, 128.22, 128.43, 128.50, 129.10, 129.22, 136.39, 136.41, 138.70, 138.84, 167.43, 167.90, 202.15, 202.77 (1 signal missing due to overlapping). HPLC: Chiralpak AS-H, n-Hexane/EtOH = 90:10, flow rate 1.0 mL/min, λ = 210 nm, T = 20 °C. Minor diastereomer: enantiomers: tR = 14.066 min (minor); 17.773 min (major)—94% ee. Major diastereomer: enantiomers: tR = 17.164 min (major); 19.406 min (minor)—91% ee.

3.33. Synthesis of Methyl 2-(2-((3-Methylbut-2-en-1-yl)oxy)acetyl)-3-(nitromethyl)octadecanoate (rac-17e)

Following GP3, prepared from methyl 4-((3-methylbut-2-en-1-yl)oxy)-3-oxobutanoate (2c) (0.3 mmol, 60.1 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst X, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:5). rac-17e Yield: 52.2 mg (0.108 mmol, 54%, two diastereomers in a ratio of 51:49 in CDCl₃) of colorless oil. EI-HRMS: m/z = 501.3887 (M+NH₄⁺); C₂₇H₅₃N₂O₆ requires m/z = 501.3898 (M+NH₄⁺); ν_max 2923, 2853, 1726, 1553, 1435, 1379, 1250, 1199, 1158, 1092, 1000, 780, 722 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃) for both diastereomers: δ 0.88 (t, J = 7.0 Hz, 3H), 1.18–1.51 (m, 28H), 1.68 (dd, J = 1.4, 4.8 Hz, 3H), 1.77 (dd, J = 1.2, 4.1 Hz, 3H), 2.85–2.93 (m, 1H), 3.73 (s, 1.5H), 3.74 (s, 1.5H), 3.94–4.15 (m, 5H), 4.46 (dd, J = 7.1, 13.3 Hz, 0.5H), 4.53 (dd, J = 5.7, 13.2 Hz, 0.5H), 4.59–4.69 (m, 1H), 5.27–5.34 (m, 1H). ¹³C-NMR (151 MHz, CDCl₃) for both diastereomers: δ 14.28, 18.19, 18.21, 22.84, 25.96, 26.88, 27.05, 29.38, 29.45, 29.51, 29.66, 29.75, 29.80, 29.83, 29.85, 30.29, 32.07, 36.10, 36.30, 52.67, 52.82, 54.92, 55.32, 67.99, 68.00, 74.63, 74.73, 76.40, 76.75, 119.82, 119.92, 138.71, 138.89, 168.55, 168.56, 203.55, 203.88 (17 signals missing due to overlapping).

3.34. Synthesis of Methyl 2-((R)-2-Nitro-1-phenylethyl)-3-oxooctadecanoate (17f)

Following GP3 and GP4, prepared from methyl 3-oxooctadecanoate (2d) (0.3 mmol, 93.7 mg) and trans-β-nitrostyrene (12) (0.2 mmol, 29.8 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:10). rac-17f Yield: 34.2 mg (0.074 mmol, 37%, two diastereomers in a ratio of 56:44 in CDCl₃) of white solid. 17f Yield: 55.4 mg (0.120 mmol, 60%, two diastereomers in a ratio of 50:50 in CDCl₃) of white solid; m.p. = 60.0–61.2 °C. EI-HRMS: m/z = 462.3214 (MH⁺); C₂₇H₄₄NO₅ requires m/z = 462.3214 (MH⁺); ν_max 2915, 2850, 1742, 1711, 1550, 1496, 1471, 1455, 1438, 1383, 1334, 1281, 1245, 1208, 1173, 1128, 1092, 1072, 1033, 1004, 983, 918, 892, 853, 765, 718, 700, 616 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for the major diastereomer: δ 0.88 (t, J = 6.9 Hz, 3H), 0.94–1.04 (m, 2H), 1.06–1.39 (m, 22H), 1.51–1.60 (m, 2H), 2.13 (dt, J = 7.2, 17.8, 1H), 2.38–2.50 (m, 1H), 3.76 (s, 3H), 4.03 (d, J = 10.0 Hz, 1H), 4.19–4.28 (m, 1H), 4.75–4.89 (m, 2H), 7.16–7.22 (m, 2H), 7.24–7.34 (m, 3H). ¹H-NMR (500 MHz, CDCl₃) for the minor diastereomer: δ 2.61 (dt, J = 7.4, 17.7 Hz, 1H), 3.52 (s, 3H), 4.13 (d, J = 9.5 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃) for both diastereomers: δ 14.27, 22.83, 23.05, 23.39, 28.74, 29.00, 29.33, 29.45, 29.48, 29.50, 29.56, 29.68, 29.73, 29.76, 29.78, 29.80, 29.83, 32.06, 42.53, 42.86, 43.50, 43.84, 52.87, 53.05, 60.97, 61.34, 77.67, 77.93, 127.94, 128.11, 128.42, 128.50, 129.15, 129.26, 136.44, 136.63, 167.62, 168.14, 202.76, 203.81 (10 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/EtOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Minor diastereomer: enantiomers: tR = 7.287 min (minor); 22.511 min (major)—95% ee. Major diastereomer: enantiomers: tR = 8.963 min (major); 13.215 min (minor)—96% ee.

3.35. Synthesis of Methyl 2-(1-Nitroheptadecan-2-yl)-3-oxooctadecanoate (rac-17g)

Following GP3, prepared from methyl 3-oxooctadecanoate (2d) (0.3 mmol, 93.7 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst X, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:10). rac-17g Yield: 78.7 mg (0.132 mmol, 66%, two diastereomers in a ratio of 68:32 in CDCl₃) of white solid; m.p. = 40.0–40.9 °C. EI-HRMS: m/z = 594.5108 (M−H⁺)⁻; C₃₆H₆₈NO₅ requires m/z = 594.5103 (M−H⁺)⁻; ν_max 2955, 2914, 2849, 1730, 1707, 1556, 1543, 1470, 1435, 1402, 1380, 1243, 1204, 1128, 1073, 1000, 863, 719 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃) for both diastereomers: δ 0.88 (t, J = 7.0, 6H), 1.11–1.46 (m, 52H), 1.55–1.62 (m, 2H), 2.47–2.55 (m, 1H), 2.57–2.66 (m, 1H), 2.79–2.90 (m, 1H), 3.75 (s, 2.04H), 3.75 (s, 0.96H), 3.76–3.81 (m, 1H), 4.49–4.57 (m, 1H), 4.59–4.67 (m, 1H). ¹³C-NMR (151 MHz, CDCl₃) for both diastereomers: δ 14.28, 22.85, 23.46, 23.50, 26.80, 26.91, 29.08, 29.10, 29.42, 29.45, 29.48, 29.50, 29.52, 29.60, 29.65, 29.67, 29.75, 29.81, 29.83, 29.85, 30.22, 32.08, 36.72, 36.77, 43.43, 43.60, 52.79, 52.91, 59.33, 59.72, 76.16, 76.57, 168.77, 168.81, 204.33, 204.46 (36 signals missing due to overlapping).

3.36. Synthesis of Methyl 2-((R)-2-Nitro-1-phenylethyl)-3-oxoicosanoate (17h)

Following GP3 and GP4, prepared from methyl 3-oxoicosanoate (2e) (0.3 mmol, 102.2 mg) and trans-β-nitrostyrene (12) (0.2 mmol, 29.8 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:10). rac-17h Yield: 43.1 mg (0.088 mmol, 44%, two diastereomers in a ratio of 54:46 in CDCl₃) of white solid. 17h Yield: 52.9 mg (0.108 mmol, 54%, two diastereomers in a ratio of 48:52 in CDCl₃) of white solid; m.p. = 42.2–44.7 °C. EI-HRMS: m/z = 490.3524 (MH⁺); C₂₉H₄₈NO₅ requires m/z = 490.3527 (MH⁺); ν_max 2914, 2849, 1737, 1712, 1555, 1496, 1471, 1455, 1433, 1404, 1378, 1271, 1198, 1168, 1113, 1082, 982, 891, 765, 716, 699 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for the major diastereomer: δ 0.88 (t, J = 6.9 Hz, 3H), 1.06–1.37 (m, 30H), 2.38–2.50 (m, 1H), 2.61 (dt, J = 7.4, 17.7 Hz, 1H), 3.52 (s, 3H), 4.13 (d, J = 9.4 Hz, 1H), 4.19–4.28 (m, 1H), 4.74–4.89 (m, 2H), 7.16–7.22 (m, 2H), 7.24–7.33 (m, 3H). ¹H-NMR (500 MHz, CDCl₃) for the minor diastereomer: δ 0.94–1.04 (m, 2H), 1.51–1.60 (m, 2H), 2.13 (dt, J = 7.1, 17.7 Hz, 1H), 3.75 (s, 3H), 4.03 (d, J = 10.0 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃) for both diastereomers: δ 14.25, 22.82, 23.03, 23.37, 28.72, 28.99, 29.32, 29.43, 29.47, 29.49, 29.55, 29.67, 29.72, 29.75, 29.77, 29.79, 29.82, 32.05, 42.51, 42.86, 43.48, 43.83, 52.84, 53.02, 60.94, 61.33, 77.65, 77.92, 127.93, 128.10, 128.39, 128.47, 129.13, 129.24, 136.44, 136.63, 167.61, 168.12, 202.74, 203.79 (14 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/EtOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Major diastereomer: enantiomers: tR = 8.838 min (minor); 26.885 min (major)—96% ee. Minor diastereomer: enantiomers: tR = 10.913 min (major); 15.371 min (minor)—96% ee.

3.37. Synthesis of Methyl 2-(1-Nitroheptadecan-2-yl)-3-oxoicosanoate (rac-17i)

Following GP3, prepared from methyl 3-oxoicosanoate (2e) (0.3 mmol, 102.2 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst X, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:10). rac-17i Yield: 52.4 mg (0.084 mmol, 42%, two diastereomers in a ratio of 50:50 in CDCl₃) of white solid; m.p. = 42.0–43.9 °C. EI-HRMS: m/z = 622.5416 (M−H⁺)⁻; C₃₈H₇₃NO₅ requires m/z = 622.5421 (M−H⁺)⁻; ν_max 2956, 2915, 2848, 1731, 1706, 1556, 1542, 1470, 1435, 1402, 1379, 1349, 1241, 1205, 1128, 1108, 1078, 1001, 719 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for both diastereomers: δ 0.87 (t, J = 6.9 Hz, 6H), 1.08–1.44 (m, 56H), 1.53–1.61 (m, 2H), 2.45–2.55 (m, 1H), 2.56–2.66 (m, 1H), 2.78–2.89 (m, 1H), 3.74 (s, 1.5H), 3.74 (s, 1.5H), 3.75 (d, J = 6.9 Hz, 0.5H), 3.79 (d, J = 7.6 Hz, 0.5H), 4.45–4.55 (m, 1H), 4.62 (td, J = 4.6, 13.5 Hz, 1H). ¹³C-NMR (126 MHz, CDCl₃) for both diastereomers: δ 14.25, 22.83, 23.43, 23.48, 26.77, 26.88, 29.06, 29.08, 29.40, 29.43, 29.46, 29.48, 29.50, 29.59, 29.64, 29.71, 29.74, 29.79, 29.82, 29.84, 30.20, 32.06, 36.68, 36.74, 43.38, 43.56, 52.74, 52.86, 59.30, 59.69, 76.13, 76.54, 168.74, 168.78, 204.28, 204.41 (40 signals missing due to overlapping).

3.38. Synthesis of Tert-butyl 2-((R)-2-nitro-1-phenylethyl)-3-oxoicosanoate (17j)

Following GP3 and GP4, prepared from tert-butyl 3-oxoicosanoate (2f) (0.3 mmol, 114.8 mg) and trans-β-nitrostyrene (12) (0.2 mmol, 29.8 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:10). rac-17j Yield: 42.5 mg (0.080 mmol, 40%, two diastereomers in a ratio of 61:39 in CDCl₃) of white solid. 17j Yield: 50.0 mg (0.094 mmol, 47%, two diastereomers in a ratio of 36:64 in CDCl₃) of white solid; m.p. = 54.0–56.4 °C. EI-HRMS: m/z = 549.4273 (M+NH₄⁺); C₃₂H₅₇N₂O₅ requires m/z = 549.4262 (M+NH₄⁺); ν_max 2916, 2849, 1731, 1712, 1553, 1496, 1468, 1434, 1394, 1378, 1284, 1250, 1148, 1126, 1092, 1062, 982, 914, 838, 770, 751, 720, 700 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for the major diastereomer: δ 0.88 (t, J = 6.9 Hz, 3H), 0.98–1.07 (m, 2H), 1.09–1.39 (m, 28H), 1.46 (s, 9H), 1.55–1.63 (m, 1H), 2.14 (dt, J = 7.1, 17.5 Hz, 1H), 2.38–2.52 (m, 1H), 3.91 (d, J = 9.9 Hz, 1H), 4.12–4.23 (m, 1H), 4.65–4.76 (m, 1H), 7.16–7.34 (m, 5H). ¹H-NMR (500 MHz, CDCl₃) for the minor diastereomer: δ 2.62 (dt, J = 7.4, 17.4 Hz, 1H), 4.01 (d, J = 10.1 Hz, 1H), 4.77–4.90 (m, 2H). ¹³C-NMR (126 MHz, CDCl₃) for both diastereomers: δ 14.26, 22.83, 23.18, 23.53, 27.52, 27.98, 28.90, 29.15, 29.38, 29.48, 29.50, 29.56, 29.69, 29.73, 29.76, 29.80, 29.83, 32.06, 42.54, 42.79, 42.87, 43.59, 62.16, 62.51, 78.06, 78.40, 82.95, 83.40, 128.18, 128.29, 128.32, 128.36, 128.95, 129.14, 136.81, 136.84, 166.04, 166.75, 203.13, 203.98 (16 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/EtOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Minor diastereomer: enantiomers: tR = 6.051 min (minor); 8.241 min (major)—93% ee. Major diastereomer: enantiomers: tR = 6.768 min (minor); 7.403 min (major)—98% ee.

3.39. Synthesis of Tert-butyl 2-(1-nitroheptadecan-2-yl)-3-oxoicosanoate (rac-17k)

Following GP3, prepared from tert-butyl 3-oxoicosanoate (2f) (0.3 mmol, 114.8 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst X, 24 h; isolation by column chromatography (first CC: CH₂Cl₂/petroleum ether = 1:3; second CC: EtOAc/petroleum ether = 1:10). rac-17k Yield: 51.9 mg (0.079 mmol, 39%, two diastereomers in a ratio of 66:34 in CDCl₃) of white solid; m.p. = 41.2–45.0 °C. EI-HRMS: m/z = 664.5894 (M−H⁺)⁻; C₄₁H₇₈NO₅ requires m/z = 664.5886 (M−H⁺)⁻; ν_max 2916, 2848, 1726, 1703, 1556, 1545, 1466, 1370, 1256, 1210, 1157, 1047, 845, 720, 618 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for both diastereomers: δ 0.88 (t, J = 7.0 Hz, 6H), 1.12–1.44 (m, 56H), 1.47 (s, 9H), 1.55–1.63 (m, 2H), 2.45–2.54 (m, 1H), 2.56–2.67 (m, 1H), 2.76–2.86 (m, 1H), 3.63 (d, J = 6.9, 0.34H), 3.66 (d, J = 7.5 Hz, 0.66H), 4.48–4.56 (m, 1H), 4.57–4.67 (m, 1H). ¹³C-NMR (126 MHz, CDCl₃) for both diastereomers: δ 14.26, 22.84, 23.55, 23.60, 26.79, 26.88, 28.03, 28.07, 29.23, 29.49, 29.51, 29.54, 29.60, 29.67, 29.76, 29.81, 29.83, 29.85, 30.19, 32.08, 36.66, 36.77, 43.26, 43.47, 60.43, 60.98, 76.40, 76.77, 83.01, 83.07, 167.40, 167.43, 204.68, 204.83 (44 signals missing due to overlapping).

3.40. Synthesis of Methyl (11Z,14Z)-2-((R)-2-Nitro-1-phenylethyl)-3-oxoicosa-11,14-dienoate (17l)

Following GP3 and GP4, prepared from methyl (11Z,14Z)-3-oxoicosa-11,14-dienoate (2g) (0.3 mmol, 101.0 mg) and trans-β-nitrostyrene (12) (0.2 mmol, 29.8 mg), organocatalyst VIII, 24 h; isolation by column chromatography (EtOAc/petroleum ether = 1:20). rac-17l Yield: 58 mg (0.120 mmol, 60%, two diastereomers in a ratio of 52:48 in CDCl₃) of colorless oil. 17l Yield: 60.2 mg (0.124 mmol, 62%, two diastereomers in a ratio of 51:49 in CDCl₃) of colorless oil. EI-HRMS: m/z = 508.3032 (MNa⁺); C₂₉H₄₃NO₅Na requires m/z = 508.3032 (MNa⁺); ν_max 3009, 2925, 2855, 1744, 1717, 1554, 1496, 1455, 1434, 1377, 1243, 1168, 981, 914, 765, 699 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃) for both diastereomers: δ 0.89 (td, J = 1.5, 7.0 Hz, 3H), 0.95–1.05 (m, 1H), 1.10–1.16 (m, 1H), 1.16–1.21 (m, 1H), 1.23–1.40 (m, 12H), 1.52–1.60 (m, 1H), 1.97–2.07 (m, 4H), 2.13 (dt, J = 7.2, 17.8 Hz, 0.5H), 2.39–2.49 (m, 1H), 2.61 (dt, J = 7.4, 17.7 Hz, 0.5H), 2.77 (q, J = 6.5 Hz, 2H), 3.52 (s, 1.5H), 3.76 (s, 1.5H), 4.03 (d, J = 10.0 Hz, 0.5H), 4.13 (d, J = 9.4 Hz, 0.5H), 4.19–4.27 (m, 1H), 4.74–4.88 (m, 2H), 5.28–5.43 (m, 4H), 7.17–7.21 (m, 2H), 7.22–7.34 (m, 3H). ¹³C-NMR (151 MHz, CDCl₃) for both diastereomers: δ 14.22, 22.71, 23.03, 23.37, 25.76, 27.30, 27.31, 27.34, 28.70, 28.97, 29.13, 29.20, 29.24, 29.36, 29.48, 29.67, 29.72, 31.66, 42.53, 42.87, 43.48, 43.83, 52.87, 53.05, 60.98, 61.35, 77.67, 77.93, 127.94, 128.00, 128.02, 128.12, 128.20, 128.23, 128.43, 128.51, 129.16, 129.26, 130.13, 130.38, 136.45, 136.64, 168.14, 202.70, 203.76 (9 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/EtOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Minor diastereomer: enantiomers: tR = 7.439 min (minor); 19.360 min (major)—96% ee. Major diastereomer: enantiomers: tR = 9.402 min (major); 12.992 min (minor)—96% ee.

3.41. Synthesis of Methyl (4S)-7-((Tert-butoxycarbonyl)amino)-2-(2-nitro-1-phenylethyl)-3-oxo-4-stearamidoheptanoate (17m)

Following GP3, prepared from methyl (S)-7-((tert-butoxycarbonyl)amino)-3-oxo-4-stearamidoheptanoate (2h) (0.2 mmol, 111.0 mg) and trans-β-nitrostyrene (12) (0.3 mmol, 44.7 mg), organocatalyst X, 48 h; isolation by column chromatography (1. EtOAc/petroleum ether = 1:2; 1. EtOAc/petroleum ether = 1:1). 17m Yield: 100.0 mg (0.142 mmol, 71%, 4 diastereomers in a ratio of 27:21:24:28 in CDCl₃) of white semisolid. EI-HRMS: m/z = 704.4827 (MH⁺); C₃₉H₆₆N₃O₈ requires m/z = 704.4844 (MH⁺); ν_max 3375, 2920, 2851, 1739, 1720, 1687, 1648, 1551, 1518, 1455, 1436, 1365, 1247, 1214, 1168, 1089, 1005, 872, 764, 720, 701, 617 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for 4 diastereomers: δ 0.88 (t, J = 6.9, 3H), 1.05–1.39 (m, 29H), 1.42–1.45 (m, 9H), 1.46–1.68 (m, 4H), 1.71–1.86 (m, 1H), 2.02–2.28 (m, 2H), 2.77–3.22 (m, 2H), 3.48, 3.49, 3.74, 3.77 (4 × s, 3H), 4.22–4.96 (m, 6H), 5.83–6.68 (m, 1H), 7.18–7.35 (m, 5H). ¹³C-NMR (126 MHz, CDCl₃) for 4 diastereomers: δ 14.24, 22.80, 25.55, 25.62, 25.67, 25.90, 26.01, 26.20, 26.30, 26.90, 26.95, 27.05, 27.20, 28.48, 28.49, 29.38, 29.40, 29.43, 29.45, 29.47, 29.60, 29.61, 29.63, 29.73, 29.75, 29.77, 29.81, 32.03, 36.04, 36.40, 36.44, 36.50, 39.56, 39.71, 39.75, 42.54, 42.63, 43.10, 43.25, 52.84, 53.02, 53.11, 53.36, 57.89, 58.13, 58.32, 58.44, 58.62, 58.97, 59.18, 77.27, 77.36, 77.58, 77.70, 79.48, 79.52, 79.67, 79.70, 128.09, 128.14, 128.27, 128.36, 128.42, 128.50, 129.04, 129.18, 129.21, 136.21, 136.27, 136.50, 136.55, 156.26, 156.41, 156.55, 156.59, 166.95, 167.15, 167.30, 167.66, 173.10, 173.47, 173.85, 174.11, 200.93, 201.85, 202.18, 202.94 (69 signals missing due to overlapping).

3.42. Synthesis of Methyl 2-((S)-5-((Tert-butoxycarbonyl)amino)-2-stearamidopentanoyl)-3-(nitromethyl)octadecanoate (17n)

Following GP3 and GP4, prepared from methyl (S)-7-((tert-butoxycarbonyl)amino)-3-oxo-4-stearamidoheptanoate (2h) (0.2 mmol, 111.0 mg) and (E)-1-nitroheptadec-1-ene (16) (0.3 mmol, 85.0 mg), organocatalyst X, 48 h; isolation by column chromatography (1. EtOAc/petroleum ether = 1:3; 1. EtOAc/petroleum ether = 1:2); 17n Yield: 129.1 mg (0.154 mmol, 77%, 4 diastereomers in a ratio of 26:28:25:21 in CDCl₃) of white solid. Organocatalyst VIII, 48 h; isolation by column chromatography (1. EtOAc/petroleum ether = 1:3; 1. EtOAc/petroleum ether = 1:2); 17n Yield: 147.5 mg (0.176 mmol, 88%, 4 diastereomers in a ratio of 45:11:8:36 in CDCl₃) of white solid. EI-HRMS: m/z = 838.6860 (MH⁺); C₄₈H₉₂N₃O₈ requires m/z = 838.6879 (MH⁺); ν_max 3361, 2917, 2850, 1741, 1718, 1687, 1644, 1553, 1524, 1467, 1366, 1250, 1222, 1171, 1039, 1011, 869, 721, 646 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for 4 diastereomers: δ 0.88 (t, J = 6.9 Hz, 6H), 1.10–1.39 (m, 57H), 1.44 (s, 9H), 1.48–1.58 (m, 2H), 1.58–1.67 (m, 2H), 1.87–1.99 (m, 1H), 2.20–2.27 (m, 2H), 2.80–2.93 (m, 1H), 3.05–3.24 (m, 2H), 3.73, 3.74, 3.76, 3.77 (4 × s, 3H), 3.99 (d, J = 6.3 Hz, 0.206H), 4.04 (d, J = 6.9 Hz, 0.255H), 4.09 (d, J = 5.2 Hz, 0.284H), 4.15 (d, J = 7.0 Hz, 0.255H), 4.40–4.80 (m, 4H), 6.42–6.58 (m, 1H). ¹³C-NMR (126 MHz, CDCl₃) for 4 diastereomers: δ 14.23, 22.80, 25.67, 25.70, 26.36, 26.74, 26.77, 26.83, 26.87, 27.08, 27.43, 28.48, 29.42, 29.44, 29.46, 29.48, 29.64, 29.66, 29.72, 29.73, 29.75, 29.78, 29.82, 30.43, 30.52, 32.04, 36.37, 36.43, 36.53, 36.60, 37.22, 37.42, 39.76, 39.79, 39.82, 39.83, 52.77, 52.92, 53.00, 53.15, 55.92, 56.15, 56.47, 58.05, 58.26, 58.39, 58.62, 76.25, 76.43, 76.48, 77.36, 79.56, 156.45, 168.14, 168.38, 168.43, 168.46, 173.58, 173.64, 173.71, 173.80, 203.24, 203.40, 203.67 (128 signals missing due to overlapping).

3.43. Synthesis of Methyl (4S)-2-(2-Nitro-1-phenylethyl)-3-oxo-4,7-distearamidoheptanoate (17o)

Following GP3, prepared from methyl (S)-3-oxo-4,7-distearamidoheptanoate (2i) (0.2 mmol, 144.1 mg) and trans-β-nitrostyrene (12) (0.3 mmol, 44.7 mg), organocatalyst X, 48 h; isolation by column chromatography (first column chromatography: EtOAc/petroleum ether = 1:1; second column chromatography: CH₂Cl₂/MeOH = 75:1). 17o Yield: 50.5 mg (0.058 mmol, 29%, 4 diastereomers in a ratio of 24:22:30:24 in CDCl₃) of light orange solid. EI-HRMS: m/z = 870.6936 (MH⁺); C₅₂H₉₂N₃O₇ requires m/z = 870.6930 (MH⁺); ν_max 3292, 2916, 2848, 1745, 1720, 1638, 1552, 1462, 1434, 1377, 1274, 1240, 1221, 1205, 1168, 1114, 755, 719, 700 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for 4 diastereomers: δ 0.88 (t, J = 6.9 Hz, 6H), 0.99–1.42 (m, 56H), 1.42–1.68 (m, 6H), 1.69–1.86 (m, 1H), 2.05–2.29 (m, 4H), 2.91–3.35 (m, 3H), 3.47, 3.48, 3.74, 3.77 (4 × s, 3H), 4.22–4.65 (m, 3H), 4.72–4.95 (m, 2H), 5.57–5.85 (m, 1H), 6.14 (d, J = 7.9 Hz, 0.244H), 6.56 (d, J = 7.9 Hz, 0.296H), 6.85 (br s, 0.225H), 6.93 (d, J = 7.1 Hz, 0.235H), 7.18–7.34 (m, 5H). ¹³C-NMR (126 MHz, CDCl₃) for 4 diastereomers: δ 14.24, 22.81, 25.55, 25.60, 25.63, 25.67, 25.77, 25.91, 26.08, 26.27, 26.57, 26.77, 27.03, 27.27, 29.41, 29.43, 29.48, 29.50, 29.64, 29.66, 29.78, 29.80, 29.83, 32.04, 36.02, 36.38, 36.46, 36.89, 36.91, 38.52, 38.61, 38.68, 38.71, 42.54, 42.64, 43.09, 43.31, 52.83, 52.99, 53.14, 53.32, 58.08, 58.17, 58.19, 58.25, 58.27, 58.82, 58.95, 59.10, 77.29, 77.36, 77.56, 77.65, 77.69, 128.11, 128.16, 128.26, 128.36, 128.42, 128.49, 129.03, 129.17, 136.21, 136.33, 136.52, 136.60, 167.03, 167.21, 167.40, 167.69, 173.31, 173.74, 173.80, 174.07, 174.08, 174.21, 201.14, 201.89, 202.14, 203.10 (128 signals missing due to overlapping).

3.44. Synthesis of Methyl 2-((S)-2,5-Distearamidopentanoyl)-3-(nitromethyl)octadecanoate (17p)

Following GP3 and GP4, prepared from methyl (S)-3-oxo-4,7-distearamidoheptanoate (2i) (0.2 mmol, 144.1 mg) and (E)-1-nitroheptadec-1-ene (16) (0.3 mmol, 85.0 mg), organocatalyst X, 48 h; isolation by column chromatography (1. EtOAc/petroleum ether = 1:3; 1. EtOAc/petroleum ether = 1:1); 17p Yield: 50.2 mg (0.05 mmol, 25%, 4 diastereomers in a ratio of 25:25:27:23 in CDCl₃) of light orange solid. Organocatalyst VIII, 48 h; isolation by column chromatography (1. EtOAc/petroleum ether = 1:3; 1. EtOAc/petroleum ether = 1:1); 17p Yield: 46.2 mg (0.046 mmol, 23%, 4 diastereomers in a ratio of 39:11:12:38 in CDCl₃) of light orange solid. EI-HRMS: m/z = 1004.8949 (MH⁺); C₆₁H₁₁₈N₃O₇ requires m/z = 1004.8964 (MH⁺); ν_max 3293, 2916, 2849, 1746, 1721, 1639, 1552, 1463, 1378, 1274, 1257, 1240, 1222, 1204, 719, 615 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for 4 diastereomers: δ 0.88 (t, J = 6.9, 9H), 1.07–1.46 (m, 88H), 1.48–1.70 (m, 7H), 1.83–1.98 (m, 1H), 2.14–2.21 (m, 2H), 2.21–2.30 (m, 2H), 2.81–2.92 (m, 1H), 3.17–3.28 (m, 1H), 3.28–3.40 (m, 1H), 3.73, 3.74, 3.76, 3.77 (4 × s, 3H), 3.98 (d, J = 5.9 Hz, 0.235H), 4.03 (d, J = 7.0 Hz, 0.270H), 4.08 (d, J = 5.2 Hz, 0.249H), 4.14 (d, J = 7.0 Hz, 0.246H), 4.37–4.78 (m, 3H), 5.79–5.89 (m, 1H), [6.72 (d, J = 7.6 Hz), 6.76 (d, J = 7.7 Hz), 6.77 (d, J = 7.8 Hz), 6.89 (d, J = 7.6 Hz); 1H]. ¹³C-NMR (126 MHz, CDCl₃) for 4 diastereomers: δ 22.81, 25.65, 25.68, 25.69, 25.91, 25.93, 26.35, 26.41, 26.45, 26.49, 26.75, 26.79, 26.85, 26.89, 27.11, 27.40, 27.57, 29.44, 29.45, 29.49, 29.52, 29.57, 29.66, 29.67, 29.69, 29.71, 29.74, 29.76, 29.79, 29.81, 29.83, 30.44, 30.59, 32.05, 36.34, 36.39, 36.46, 36.48, 36.56, 36.92, 37.19, 37.40, 38.78, 38.81, 52.80, 52.94, 52.97, 53.16, 55.83, 55.89, 56.43, 56.55, 58.28, 58.41, 58.46, 58.56, 76.25, 76.50, 76.58, 77.36, 168.25, 168.36, 168.52, 173.80, 173.90, 173.94, 173.95, 174.02, 203.12, 203.63, 203.70 (173 signals missing due to overlapping).

3.45. Organocatalyzed Michael Addition of Pyrrolones 11 to Nitroalkene 16—General Procedure for the Preparation of Racemic Mixtures—General Procedure 5 (GP5)

To a solution/suspension of (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg; 1.0 equivalent) and the achiral organocatalyst X (0.04 mmol, 0.2 equivalents, 16.4 mg) in anhydrous toluene (1 mL) under argon at room temperature, pyrrolone 11 (0.3 mmol, 1.5 equivalents) was added, and the resulting reaction mixture was stirred at room temperature for 48–72 h. The volatiles were evaporated in vacuo, and the residue was purified by column chromatography (Silica gel 60, mobile phase). The fractions containing the pure racemic product rac-18 were combined, and the volatiles were evaporated in vacuo. The product rac-18 was fully characterized and analyzed by HPLC.

3.46. Organocatalyzed Michael Addition of Pyrrolones 11 to Nitroalkene 16—General Procedure for the Organocatalyzed Asymmetric Addition—General Procedure 6 (GP6)

To a solution/suspension of (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg; 1.0 equivalent) and the chiral organocatalyst I (0.02 mmol, 0.1 equivalents, 10.9 mg) in anhydrous toluene (1 mL) under argon at room temperature, pyrrolone 11 (0.3 mmol, 1.5 equivalents) was added, and the resulting reaction mixture was stirred at room temperature for 48–72 h. The volatiles were evaporated in vacuo, and the residue was purified by column chromatography (Silica gel 60, mobile phase). The fractions containing the pure chiral nonracemic product 18 were combined, and the volatiles were evaporated in vacuo. The product 18 was fully characterized and analyzed by HPLC.

3.47. Synthesis of 1-(Tert-butyl) 3-Methyl (S)-5-benzyl-5-((S)-1-nitroheptadecan-2-yl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (18a)

Following GP5 and GP6, prepared from 1-(tert-butyl) 3-methyl 5-benzyl-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11a) (0.3 mmol, 99.4 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst I, 48 h; isolation by column chromatography (EtOAc/petroleum ether = 1:5). rac-18a Yield: 94.7 mg (0.154 mmol, 77%, diastereomer 1/diastereomer 2 = 97:3 in CDCl₃) of colorless oil. 18a Yield: 84.8 mg (0.138 mmol, 69%, diastereomer 1/diastereomer 2 = 97:3 in CDCl₃) of colorless oil. EI-HRMS: m/z = 615.3970 (MH⁺); C₃₅H₅₅N₂O₇ requires m/z = 615.4004 (MH⁺); ν_max 2923, 2853, 1732, 1713, 1581, 1554, 1497, 1456, 1438, 1370, 1295, 1224, 1143, 1089, 1063, 992, 914, 876, 843, 760, 725, 703, 628 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for diastereomer 1: δ 0.88 (t, J = 6.9 Hz, 3H), 1.07–1.43 (m, 26H), 1.44–1.85 (m, 11H), 3.26–3.54 (m, 3H), 3.77 (s, 3H), 4.31 (dd, J = 5.1, 13.7 Hz, 1H), 4.51 (br s, 1H), 6.95–7.03 (m, 2H), 7.11–7.21 (m, 3H), 8.60 (br s, 1H). ¹H-NMR (500 MHz, CDCl₃) for diastereomer 2: δ 3.71 (s, 3H). ¹³C-NMR (126 MHz, CDCl₃) for diastereomer 1: δ 14.26, 22.83, 27.55, 27.74, 28.10, 29.50, 29.52, 29.61, 29.63, 29.73, 29.78, 29.79, 29.82, 29.83, 32.06, 39.94, 43.20, 51.92, 76.56, 85.81, 112.39, 127.69, 128.43, 129.63, 133.25, 147.60, 161.78, 164.91, 196.43 (2 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/iPrOH = 95:5, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Major diastereomer: enantiomers: tR = 9.350 min (major); 13.217 min (minor)—82% ee.

3.48. Synthesis of 1-(Tert-butyl) 3-Methyl 5-(4-(((Benzyloxy)carbonyl)amino)butyl)-5-(1-nitroheptadecan-2-yl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (18b)

Following GP5 and GP6, prepared from 1-(tert-butyl) 3-methyl 5-(4-(((benzyloxy)carbonyl)amino)butyl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11b) (0.3 mmol, 134.0 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst I, 72 h; isolation by column chromatography (EtOAc/petroleum ether = 1:2). rac-18b Yield: 94.9 mg (0.130 mmol, 65%, diastereomer 1/diastereomer 2 = 90:10 in CDCl₃) of colorless oil. 18b Yield: 26.3 mg (0.036 mmol, 18%, diastereomer 1/diastereomer 2 = 26:74 in CDCl₃) of colorless oil. EI-HRMS: m/z = 730.4644 (MH⁺); C₄₀H₆₄N₃O₉ requires m/z = 730.4637 (MH⁺); ν_max 3675, 3369, 2923, 2854, 1711, 1582, 1553, 1455, 1438, 1394, 1371, 1280, 1226, 1140, 1067, 846, 763, 697 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) for diastereomer 1: δ 0.88 (t, J = 6.9 Hz, 3H), 0.91–1.03 (m, 2H), 1.06–1.34 (m, 27H), 1.35–1.49 (m, 4H), 1.56 (s, 9H), 1.96–2.07 (m, 1H), 2.10–2.22 (m, 1H), 3.03–3.17 (m, 3H), 3.84 (s, 3H), 4.22 (dd, J = 5.3, 13.8 Hz, 1H), 4.30–4.41 (m, 1H), 4.71 (t, J = 6.2 Hz, 1H), 5.06 (s, 2H), 7.27–7.39 (m, 5H). ¹H-NMR (500 MHz, CDCl₃) for diastereomer 2: δ 1.58 (s, 9H), 1.87–1.96 (m, 1H), 3.28–3.36 (m, 1H), 3.83 (s, 3H), 4.28 (dd, J = 5.3, 14.6 Hz, 1H), 5.18 (dd, J = 5.5, 14.7 Hz, 1H), 9.19 (s, 1H). ¹³C-NMR (126 MHz, CDCl₃) for diastereomer 1: δ 14.26, 20.18, 22.82, 27.41, 27.49, 28.02, 29.49, 29.55, 29.62, 29.71, 29.77, 29.78, 29.81, 29.82, 32.05, 33.87, 40.61, 43.36, 5 min 2.03, 66.78, 76.35, 77.36, 86.22, 112.22, 128.24, 128.64, 136.59, 147.42, 156.40, 161.95, 165.24, 196.41 (4 signals missing due to overlapping). ¹³C-NMR (126 MHz, CDCl₃) for diastereomer 1 and diastereomer 2 (diastereomer 1/diastereomer 2 = 26:74): δ 14.26, 20.19, 20.45, 22.82, 27.18, 27.50, 27.91, 28.03, 28.12, 29.44, 29.49, 29.50, 29.56, 29.63, 29.67, 29.72, 29.75, 29.79, 29.82, 29.83, 32.05, 33.89, 40.66, 41.98, 43.37, 52.03, 52.05, 66.79, 74.38, 76.11, 76.36, 77.40, 86.21, 112.23, 112.31, 128.25, 128.65, 136.59, 147.43, 156.39, 161.92, 165.29, 196.41, 197.67 (28 signals missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/iPrOH = 90:10, flow rate 1.0 mL/min, λ = 210 nm, T = 25 °C. Major diastereomer: enantiomers: tR = 24.088 min (minor); 31.095 min (major)—57% ee. Minor diastereomer: enantiomers: tR = 26.634 min (minor); 30.099 min (major)—11% ee.

3.49. Synthesis of 1-(Tert-butyl) 3-Methyl 5-(3-(benzyloxy)-3-oxopropyl)-5-(1-nitroheptadecan-2-yl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (18c)

Following GP5 and GP6, prepared from 1-(tert-butyl) 3-methyl 5-(3-(benzyloxy)-3-oxopropyl)-4-oxo-4,5-dihydro-1H-pyrrole-1,3-dicarboxylate (11c) (0.3 mmol, 121.0 mg) and (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg), organocatalyst I, 48 h; isolation by column chromatography (EtOAc/petroleum ether = 1:5). rac-18c Yield: 92.0 mg (0.134 mmol, 67%, diastereomer 1/diastereomer 2 = 93:7 in CDCl₃) of colorless oil. 18c Yield: 42.6 mg (0.062 mmol, 31%, diastereomer 1/diastereomer 2 = 31:69 in CDCl₃) of colorless oil. EI-HRMS: m/z = 687.4224 (MH⁺); C₃₈H₅₉N₂O₉ requires m/z = 687.4215 (MH⁺); ν_max 3675, 2923, 2854, 1735, 1713, 1582, 1554, 1439, 1393, 1371, 1279, 1256, 1227, 1141, 1077, 846, 800, 752, 698 cm⁻¹. ¹H-NMR (600 MHz, CDCl₃) for diastereomer 1: δ 0.88 (t, J = 6.9 Hz, 3H), 1.17–1.34 (m, 27H), 1.35–1.46 (m, 1H), 1.56 (s, 9H), 1.98–2.06 (m, 1H), 2.09–2.17 (m, 1H), 2.37–2.45 (m, 1H), 2.48–2.55 (m, 1H), 3.13–3.20 (m, 1H), 3.83 (s, 3H), 4.25 (dd, J = 5.6, 13.8 Hz, 1H), 4.30–4.39 (m, 1H), 5.07 (s, 2H), 7.28–7.39 (m, 5H), 9.08 (s, 1H). ¹H-NMR (500 MHz, CDCl₃) for diastereomer 2: δ 1.58 (s, 9H), 2.26–2.33 (m, 1H), 2.54–2.62 (m, 1H), 3.35–3.41 (m, 1H), 3.82 (s, 3H), 5.06 (s, 2H), 5.19 (dd, J = 5.1, 14.7 Hz, 1H), 9.17 (s, 1H). ¹³C-NMR (151 MHz, CDCl₃) for diastereomer 1: δ 14.26, 22.83, 27.48, 27.60, 28.01, 29.13, 29.49, 29.50, 29.54, 29.62, 29.72, 29.77, 29.79, 29.82, 29.84, 32.06, 43.15, 52.06, 66.88, 75.92, 76.42, 86.62, 112.16, 128.44, 128.47, 128.56, 128.75, 135.56, 147.29, 161.76, 165.19, 171.48, 195.61 (1 signal missing due to overlapping). ¹³C-NMR (126 MHz, CDCl₃) for diastereomer 1 and diastereomer 2 (diastereomer 1/diastereomer 2 = 31:69): δ 14.28, 22.84, 27.17, 27.49, 28.02, 28.07, 28.11, 28.37, 29.28, 29.44, 29.50, 29.56, 29.64, 29.68, 29.73, 29.76, 29.80, 29.83, 29.85, 32.07, 41.85, 43.16, 52.06, 52.08, 66.89, 66.93, 74.46, 75.26, 75.93, 76.42, 77.39, 86.67, 112.15, 112.36, 128.45, 128.48, 128.58, 128.77, 135.51, 135.56, 147.29, 161.72, 161.77, 165.20, 165.34, 171.18, 171.49, 195.63, 196.88 (19 signal missing due to overlapping). HPLC: Chiralpak IA-3, n-Hexane/iPrOH = 90:10, flow rate 1.0 mL/min, λ = 280 nm, T = 25 °C. Major diastereomer: enantiomers: tR = 10.649 min (major); 12.074 min (minor)—68% ee. Minor diastereomer: enantiomers: tR = 9.991 min (minor); 12.514 min (major)—38% ee.

3.50. Synthesis of 4-Hydroxy-3-(1-nitroheptadecan-2-yl)furan-2(5H)-one (20)

To a solution of (E)-1-nitroheptadec-1-ene (16) (0.2 mmol, 56.7 mg) and the achiral organocatalyst X (0.04 mmol, 0.2 equivalents, 16.4 mg) in anhydrous CH₂Cl₂ (1 mL) under argon at room temperature, tetronic acid (19) (0.3 mmol, 30.0 mg) was added, and the resulting reaction mixture was stirred at room temperature for 72 h. The volatiles were evaporated in vacuo, and the residue was purified by column chromatography (Silica gel 60, EtOAc/petroleum ether = 1:1). The fractions containing the pure product 20 were combined, and the volatiles were evaporated in vacuo. Yield: 33.8 mg (0.088 mmol, 44%) of white solid; m.p. = 86.8–88.2 °C. EI-HRMS: m/z = 384.2741 (MH⁺); C₂₁H₃₈NO₅ requires m/z = 384.2744 (MH⁺); ν_max 2918, 2850, 1714, 1611, 1547, 1428, 1381, 1348, 1279, 1260, 1129, 1097, 1044, 971, 954, 780, 720, 682, 658 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃): δ 0.88 (t, J = 6.9 Hz, 3H), 1.09–1.35 (m, 26H), 1.50–1.60 (m, 1H), 1.65–1.77 (m, 1H), 3.37 (tt, J = 5.6, 9.6 Hz, 1H), 4.53 (dd, J = 5.6, 12.4 Hz, 1H), 4.71–4.81 (m, 3H), 10.97 (br s, 1H). ¹³C-NMR (126 MHz, CDCl₃): δ 14.27, 22.84, 27.28, 29.44, 29.51, 29.62, 29.76, 29.79, 29.81, 29.84, 29.86, 29.99, 32.07, 32.87, 68.14, 76.88, 99.10, 177.35, 177.91 (2 signals missing due to overlapping).

X-ray Crystallography. Single-crystal X-ray diffraction data were collected on an Agilent Technologies SuperNova Dual Diffractometer with an Atlas detector using monochromated Mo-K_α radiation (λ = 0.71073 Å) at 150 K. The data were processed using CrysAlis PRO 1.171.43.121a (Rigaku Oxford Diffraction, 2024) [71]. Using Olex2.1.2. [72], the structure was solved by direct methods implemented in SHELXS-2014/7 [73] or SHELXT-2014/7 [74] and refined by a full-matrix least-squares procedure based on F² with SHELXT-2014/7 [75]. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in geometrically calculated positions and were refined using a riding model. The drawing and the analysis of bond lengths, angles, and intermolecular interactions were carried out using Mercury [76] and Platon [77]. Structural and other crystallographic details on data collection and refinement for compound 17a have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC Deposition Number 2513139. These data can be obtained free of charge via https://www.ccdc.cam.ac.uk/structures/ (accessed on 3 January 2026) (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223-336033; e-mail: deposit@ccdc.cam.ac.uk).

4. Conclusions

Glycine-, β-alanine-, lysine-, glycolic acid-, palmitic acid-, stearic acid-, and linoleic acid-derived β-keto esters 2a–i, as well as phenylalanine-, ornithine-, and glutamic acid-derived pyrrolones 11a–c and tetronic acid (19), were used as nucleophiles for the organocatalyzed addition to trans-β-nitrostyrene (12) and the palmitic acid-derived nitroalkene 16 electrophiles. All racemic products rac-17a–l, rac-18a–c, and 20 were prepared using the achiral organocatalyst X. For products with HPLC-separable stereomers, chiral nonracemic 1,4-adducts 17a,b,d,f,h,j,l and 18a–c were resynthesized using bifunctional noncovalent organocatalysts I and/or VIII. The doubly fatty acid-derived products rac-17g,i,k could not be separated on chiral HPLC columns. β-Keto ester adducts 17a,b,d,f,h,j,l were prepared with high enantioselectivity (91–98% ee) but low diastereoselectivity (dr up to 36:64) due to the epimerizable C-2 stereocenter. The (1S,2S)-absolute configuration of the stereoisomer of adduct 17a (prepared with organocatalyst I) was determined by single-crystal X-ray diffraction analysis. Based on this, we assigned the (1R)-absolute configuration to the major enantiomer of both diastereomers of products 17a, 17b, 17d, 17f, 17h, 17j, and 17l prepared with organocatalyst VIII. Products 17m–p, prepared from the addition of lysine-derived β-keto esters 2h and 2i, showed low diastereoselectivity with both achiral X and chiral organocatalyst VIII. In the pyrrolone series, the best diastereoselectivity (dr = 97:3) and enantioselectivity (82% ee for the major diastereomer) were obtained with phenylalanine-derived pyrrolone 11a, yielding adduct 18a. The (1′S,5S)-absolute configuration of the major diastereomer of product 18a was assigned based on our previous results in the series of 1,4-adducts of pyrrolones to nitroalkene acceptors [22]. Despite certain drawbacks, such as low diastereoselectivity and challenges in separating stereomers on chiral HPLC columns, this study demonstrates the ease of assembling readily available amino acid and fatty acid building blocks under ambient conditions for the synthesis of interesting classes of products.